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Abstract
Evolutionary pressures have caused eukaryotic cells to develop various response mechanisms to
changing environments, particularly stress adaptations that have been inherited over time.
SUMOylation, the post-translational conjugation of the Small Ubiquitin-like Modifiers to a lysine
residue on target proteins, is well-documented to regulate essential processes within the cell,
including nucleocytoplasmic transport, transcription, apoptosis, protein stability, and progression
through the cell cycle (1). SUMO protein levels have been reported to increase upon diverse stress
states, including viral infection (2), cardiovascular ischemic events (3), temperature shock (4), and
cancer (5). However, very little is known about how SUMOylation is regulated within the cell,
particularly how SUMO protein levels are rapidly increased upon stress. Analysis of human
SUMO mRNA sequences obtained from the NCBI database indicates the existence of three
different transcripts, or variants (var), for the SUMO1 gene and two distinct mature mRNA
transcript variants for both the SUMO2 and SUMO3 genes. For each SUMO paralog, one of the
variants described codes for a previously unidentified protein isoform displaying a slightly
different amino acid sequence from that of the prototype paralog, hereafter referred to as the αisoform. To achieve a more thorough understanding of the molecular biology and the mechanisms
governing SUMO protein levels within the cell, in these studies we establish the relative abundance
of both the regular and alternative transcripts coding for the main SUMO paralogs in human cells,
SUMO1, SUMO2, and SUMO3, under normal and stress conditions. For all three SUMOs, the
variant transcripts that code for the well-characterized protein isoforms appears to be the most
abundant transcripts. In contrast, the one coding for the α-isoforms tends to change upon stress.
Given the known cytoprotective properties of protein SUMOylation (6), an improved
understanding of the contribution of such post-transcriptional mechanisms to the regulation of
v

SUMOylation may lead to the development of innovative therapies for conditions in which the
role of protein SUMOylation plays a critical function in host survival, including infectious diseases
such as Influenza A virus infection, and cardiovascular ischemic events such as strokes and heart
attacks.
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1. Introduction
1.1 The Central Dogma of Gene Expression
“The significance of deoxyribonucleic acid within living cells is undisputed” (7, 8). All life
essentially relies on endless cellular replication and adaptations to stress that ensure survival.
While it is presently known many of these adaptations initiate at the gene level, there is leaves
much left to discover about the regulation of these changes. Cellular instructions come from genes,
whose expression begins at the transcriptional level but can also undergo significant changes to
mitigate proper responses to external signals. Transcription generates highly specific RNA
molecules containing information within the nucleotide sequence, is the beginning of the central
dogma of molecular biology, which can be naturally and artificially manipulated at multiple levels
namely histone modification, alternative splicing, and protein biosynthesis (Fig 1)(9).

Annual Reviews.Org – Controlling Gene Expression with Small Molecules(9)

Figure 1-Dynamic Points in the Central Dogma Affect Gene Expression Levels
Instructional material contained within the DNA sequence to be transcribed into RNA. After modification,
including capping, splicing, and poly-A tailing, it is exported into the cytoplasm, where the RNA sequence
is translated into a polypeptide sequence by the ribosome (9).

Splicing is a sequence-specific post-transcriptional process in which sections of an RNA
transcript called introns are excised, and the remaining sequences called exons are merged to
construct a mature mRNA transcript. Though introns constitute a significant amount of the human
1

genome, their immense majority is eliminated from transcripts via the splicing of RNA occurring
within a ribonucleoprotein splicing machine called the supraspliceosome (10). The
supraspliceosome contains five spliceosomal small nuclear ribonucleoprotein particles, snRNPs,
and non-snRNP proteins, including regulatory splicing factors such as hnRNPs (11) and
phosphorylated Serine/Arginine-rich-proteins (Fig. 2A)(12). The five primary snRNAs (U1, U2,
U4, U5, and U6) begin the splicing process by cleaving the intron from exon one at the 5’ splice
junction to produce a bond to an adenine nucleotide in the branch-point sequence, creating what
is referred to as a lariat structure (13). This lariat formation contains an irregular 2’-5’
phosphodiester bond between the adenine and guanine nucleotides towards the end of the intron
(13). The adenine nucleotide maintains its 3’-5’ linkage, and, finally, the spliceosome complex
cleaves at the 3’ splice junction, ligating exons 1 and 2 together (13). The snRNPs then detach and
repeat for each intron.
Alternative splicing is an RNA editing method where a single gene encodes multiple protein
isoforms via exons or parts of exons and introns that are joined or skipped resulting in diverse
conformations. This editing procedure not only serves as another point of gene expression
regulation but also generates immense biodiversity by amplifying the genome causing multiple
messages to arise from a single DNA gene. The human genome contains numerous genes known
to be under the regulation of alternative splicing comprising significant housekeeping genes such
as telomerase (14), actin (15), and tubulin (16); it is estimated that about 92-94% of genes undergo
alternative splicing in which 86% produce an isoform that can vary during different developmental
stages, as well as among other tissues and individuals (17). While introns were formerly considered
as nothing more than “junk sequences”, they now appear to also contain regulatory functions by
signaling additional transcript editing machinery such as where to join and where to cut, ultimately
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serving as a switch to generate coding or non-coding RNAs from the same transcription entity
(Fig. 2B) (18) (19).

(20, 21)

Figure 2- Splicing is an Intricately Regulated Process that Contributes to Gene Expression
A: The native spliceosome houses all five snRNPs and other spliceosomal constituents providing the ultimate
platform for conformational changes. Additionally, the functional domains of the snRNPs shape an uninterrupted
segment along the surface of the large spliceosomal cavity generating a protected space for the pre-mRNA
binding and the splicing reaction to occur (20).
B: These standard forms can be combined to generate more complicated alternative splicing events in many
cases (21).
C: Splicing is Regulated by SR Proteins and hnRNPs. (Open boxes) Exons, (jagged lines) introns, (brackets)
splice sites (ss). The consensus motifs of ss are shown, and the branch point adenosine is indicated. (Dashed
lines) Two alternative splicing pathways with the middle exon are either included or excluded. Splicing is
regulated by cis-elements (ESE, ESS, ISS, and ISE) and trans-acting splicing factors (SR proteins, hnRNPs, and
unknown factors) (21).

Conversely, the splicing of introns also produces small regulatory RNAs that emerge to
add plasticity to the nature of the protein produced, its distribution in each cell type, and the timing
of its translation all of which become further points of expression regulation (22). Despite a
significant potential for error, the splicing process is conducted with extreme fidelity implying the
commitment of additional transcript qualities such as cis-regulatory elements who act as core
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splice signals in the splice selection site that can serve as either splicing enhancers or silencers.
(21). Generally, these splicing regulatory elements function through the enlistment of trans-acting
splicing factors to either activate or suppress splice site detection or spliceosome assembly via
diverse mechanisms (Fig. 2C) (23). Further RNA handling steps ensue, such as 5’end-capping
(24), 3’end polyadenylation (25), and RNA editing enzymes, ADAR1 and ADAR2 (26), still
occurring within the supraspliceosome located inside the nucleus.
In eukaryotes, mRNAs must first be transported to the cytoplasm before translation, however,
not all transcripts are translated, and some mRNA transcripts are stored for later while others are
degraded. Surveillance quality control mechanisms such as non-sense mediated decay find and
degrade mRNA sequences that lack whole open reading frames and premature stop codons to
prevent the manufacture of truncated proteins that can be fatal to the organism (27). Widespread
analyses corroborate that as many as half of all fluxes in mRNA quantities in response to stress
are caused by fluctuating rates of decay (28). Moreover, microarray experiments have revealed
that 40–50% of gene expression fluctuations in response to cellular signals occur at the level of
the mRNA stability (29). miRNAs are endogenous non-coding RNAs and are considered one of
the amplest groups of regulatory genes encompassing 1% of all genes (30). These RNA species
provide an additional regulatory pathway capable of gene silencing via complementary base
pairing among miRNAs within the 3’ untranslated regions of the target mRNAs (31). This posttranscriptional tweaking of cellular physiology in reaction to both intracellular and environmental
cues commands not only explicit temporal but also spatial control of gene expression. Another
method of influence on gene expression is the precise mRNA localization with direct implications
in cell migration (32) and differentiation (33). Hence it is now considered more evolutionarily
efficient for the cell to dictate mRNA localization because these transcripts are capable of being
4

translated tens to hundreds of times in response to local stimuli rather than transporting individual
proteins back and forth to different cellular compartments (34). This is an innovative notion
branded as the “RNA Signature” hypothesis, in which “each mRNA transcript contains an
individualized set of regulatory features that regulate its transport, localization, and translational
control” (35).
Whereas the translation of mRNA is considered a concluding point in gene expression, it is
only the initial phase in spawning a functional protein. Protein synthesis can be arranged into four
points: initiation, elongation, termination, and ribosome recycling (36). This procedure is
conducted in ribosomes located outside the nucleus within the cytosol with the aid of two further
RNA species: tRNAs, and rRNAs, as well as various proteins vital for translation. A single
mammalian cell is estimated to contain nearly 10 million ribosomes with a synthesis rate of 7500
subunits per minute (37). Initiation commences through the binding of methionyl tRNA and
mRNA to the small ribosomal subunit trailed by the large subunit who together scan the mRNA
transcript in the 5’ to 3’ direction in a cap-dependent method (38). A polypeptide chain proceeds
the elongation towards the carboxy terminus resulting with each amino acid being specified by
three bases as per the genetic code within the transcript advancing not at a continuous pace but
rather in a stop-and-go method until arriving at a stop codon (39). Termination occurs via the
concerted action of release factors eRF1 and eRF3, however, a polypeptide is not equivalent to the
production of functional proteins. The final step comprises folding into an appropriate
confirmation and association into functional complexes further sustained by molecular chaperones
who bind and stabilize unfolded or incompletely folded polypeptide chains. Further vital
modifications ensue such as cleavage and the covalent attachment of carbohydrates and lipids that
can occur on the new protein that affect the function and precise localization within the cell.
5

Translation of particular mRNAs can be regulated not only by repressor proteins but also by
noncoding miRNAs that temper the global translational function of cells in response to stress and
further physiological conditions (38). Although the level of transcription is fundamental in
facilitating the magnitude of stress responses, translational control regularly feeds urgent and
efficient fluctuations in protein levels (40). Nevertheless, because protein synthesis is viewed as a
rather costly cellular procedure, translation is chiefly repressed under most if not all types of stress
conditions. However, subsets of mRNAs that encode stress response proteins exist and facilitate
post-stress recovery and can circumvent this translational inhibition by engaging in what is referred
to as the selective translation (41). Cells can employ an assortment of mechanisms to achieve
selective translation that also contributes to the variations of elongation speed of the protein
synthesis with many of these cis-elements residing in the untranslated region of mRNAs, including
internal ribosome entry sites, upstream open reading frames, motifs with special sequences or
secondary structures, and miRNA binding sites (42, 43).
1.2 Post-Translational Modifications
Post-translational modifications are chemical reactions that can alter states of charge,
hydrophobicity, conformation, stability, and even protein function (44). These dynamic shifts are
reversible in different organelles affecting a broad range of cellular activities such as enzyme
regulation, signal transduction, and mediation of protein localization (45). In addition, protein
levels are coordinated by different rates of degradation indicating that the control of both the
quantities and actions of proteins ultimately regulates countless facets of cell behavior (46).
Presently, more than 400 distinctive protein modifications have been acknowledged such as
phosphorylation, acetylation, ubiquitination, and SUMOylation, all of which have been
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documented to affect activity, intracellular distribution, and protein interactions, and protein
longevity (47).
Phosphorylation stands as the most common and extensively studied post-translational
modification with more than 500 different kinases in mammals who conduct their reactions mainly
on the serine, threonine, and tyrosine residues of target substrate proteins (48) (49).
Ubiquitination, also a broadly studied modification regulates numerous biological processes,
including immune responses (50), apoptosis (51), and cancer (52). Contributing to the intricacy of
the proteome, ubiquitination is capable of modifying the roles of these altered proteins and
thereby the cell’s ability to counter developmental and environmental deviations where protein
degradation is needed to be sped up or slowed down (53). The process, or, conjugation of
ubiquitination is conducted by three enzymes, the ubiquitin-activating enzyme E1, the ubiquitinconjugating enzyme E2, and the ubiquitin ligase E3 (54). Moreover, these ligases are capable of
conjugating more than one ubiquitin molecule to a substrate thus forming polyubiquitin chains and
acts as a molecular signal for degradation by the 26S proteasome (54). Furthermore, the explicit
regulatory mechanism mediated by ubiquitination fluctuates with the different structures of the
poly-ubiquitin chain (55). Contending with ubiquitination for target substrates, the term SUMO
refers to a dynamic familial group of 100 amino acids called the ubiquitin-like modifiers (Ubls)
also capable of deconjugation by cysteine proteases of the sentrin-specific proteases (SENPs) (56).
1.3 Small Ubiquitin Modifiers
Since its discovery in 1996, SUMO has achieved a high degree of attention due to intriguing and
essential functions including a variety of biomedically indispensable protein substrates such as
tumor suppressor p53, C-Jun, PML, and huntingtin (57). Although SUMO and Ubiquitin proteins
exhibit similar 3-D structures and undergo similar cascades of events, ending in their post7

translational conjugation to a plethora of protein targets; unlike Ubiquitination, which simply
targets proteins for degradation, SUMOylation regulates many other vital cellular processes such
as chromosome segregation, nucleocytoplasmic transport, DNA replication, nuclear protein
import, formation of specific subnuclear structures. transcription, apoptosis, repair of DNA
damage and the inflammatory response in mammals (58). All SUMO proteins from yeast to
humans share the conserved Ubiquitin domain and the C-terminal di-glycine cleavage/attachment
site (Fig. 3) (59).

Figure 3- Small Ubiquitin Like Modifiers Protein Structures
A: Ubiquitin protein B: Neeed8 Protein and C: SUMO proteins are all similar in structure, however, SUMO
proteins can be distinguished by long-unstructured N-terminus tails. SUMO proteins are considered small,
weighing 12kDa in size. To perform post-translational modifications, SUMO proteins utilize a reversible
conjugation pathway involving three enzymes, E1, E2, and E3 attaching proteins on lysine residues and can
also form polymer chains of SUMO2 and SUMO3 proteins.

However, the most blatant difference between the SUMO proteins and Ubiquitin is a large
unstructured N-terminal extension in the SUMO proteins stretching in length between 11 and 35
amino acids. The unstructured nature suggests that it likely contributes to mediating specific
8

protein-protein interactions (PPI) (60). SUMO proteins are intriguingly among the most abundant
fraction of proteins with nearly 107 molecules/cell in the human cervix cancer cell line HeLa, only
marginally less than ubiquitin levels (61). There are three diverse well-characterized proteins
SUMO protein orthologs existent within mammals: SUMO1, SUMO2, and SUMO3, and two lessstudied paralogs: SUMO4 and SUMO5 who appear to encompass tissue constrained functions. It
was revealed that SUMO4 is encoded by an intron within the human TAB2 gene with potent
expression in kidney cells (62). However, the latter two paralogs will not be considered here. The
SUMO1 proteins display a mere 44% sequence identity with the SUMO2/3 proteins contrasted to
SUMO2 and SUMO3 who share an 86% sequence identity (63). However, distinctions between
SUMO2 and SUMO3 have not been as thoroughly investigated due to 1) high sequence
conservation and 2) a lack of means to distinguish them functionally and biochemically in vivo.
Therefore, SUMO2 and SUMO3 are almost always studied and grouped together as SUMO2/3
(63). It was shown that certain target substrates have preferential binding for the diverse
SUMO1/2/3 paralogs as described in large-scale proteomic studies which may be attributed to the
disparities in abundances of the different SUMO1/2/3 proteins (64). While most SUMO1/2/3
proteins are mostly found conjugated to their protein substrates, free SUMO2 is present in the
highest amounts followed by free SUMO3 and lastly, SUMO1 has the lowest amount of free
SUMO (65). Interestingly, conjugated SUMO1/2/3 proteins localize on the nuclear membrane,
nuclear bodies, and cytoplasm, respectively (63), while free forms of SUMO1/2/3 proteins exhibit
an even diffusion within the cell, however, there have also been documented occasional instances
in which their distribution was dynamically affected by signaling and/or stresses (66).

9

1.4 Processing of SUMO Proteins
As with many Ubiquitin and Ubiquitin-like proteins, all eukaryotic SUMO proteins are firstly
translated as immature precursors that require processing by sentrin-specific proteases (67), either
SENP1, SENP2 or SENP5 to yield a mature form with an exposed C-terminal diglycine motif that
is then necessary for adenylation by a SUMO E1(activating) enzyme (68). It should be noted there
are six SENPs who share a conserved catalytic domain in the COOH terminus that contains the
active-site pocket of His-Asp-Cys (69). The activated adenylate is then attached by an
E1(activating) enzyme and reassigned to a SUMO E2 (conjugating) enzyme also known as UBC9
(68). Ubc9 can either collaborate straightforwardly with substrates to complete the transfer of
SUMO to acceptor Lysine residues, or E3 SUMO (ligases) proteins can facilitate the conjugation
(Fig. 4) (68). The conjugation process frequently occurs through a SUMOylation consensus site
(CS) consisting of a motif of residues adjacent to the modified lysine within the substrate. This
motif corresponds to the sequence “ΨKXE,” where Ψ is a hydrophobic residue, K is the lysine
site in which the actual conjugation occurs, X is any amino acid, and E is glutamic acid (63). While
it has been shown the hydrophobic and acidic residues promote the stability of the interaction
between the substrate and the E2 enzyme (70), various forms of the SUMOylation motif have been
characterized such as negatively charged amino acid-dependent SUMO motifs (NDSMs) and
phosphorylation-dependent SUMO motifs (PDSMs) (71). PDSMs and NDSMs are speculated to
promote SUMOylation efficiency via the increasing of the interaction stability between Ubc9 and
the substrate (72). It should be noted that SUMOylation can also occur on substrate lysine residues
that don’t always conform to these known consensus sites as is the case for the well-studied K164
SUMO site in PCNA (73) (74). While data from high-throughput studies indicate that non-
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consensus SUMOylation may be a relatively common event, the mechanisms in which these sites
are recognized by the SUMOylation machinery endure to be determined (75).

Boulanger, Bossis 2021

Figure 4- SUMO Proteins Must be Processed to Achieve Conjugation
The C-terminal extensions of SUMO1/2/3 precursors are removed by SENP1/2/3/5 isopeptidases to expose a Cterminal di-glycine motif essential for SUMO activation and conjugation in an ATP-dependent manner.
SUMO1/2/3 can be removed from its substrates and SUMO chains can be depolymerized by proteases (65).

The conjugation of SUMO proteins characteristically stimulates protein-protein
interactions through the binding of SUMO conjugates to specific substrates containing SUMO
interaction motifs, also called SIMs(76). Much like ubiquitin, SUMO proteins attach as a monomer
on single or multiple lysine sites of target substrates generating mono- or multi-SUMOylated
proteins, and are habitually induced in response to cellular tension preferentially via lysine residue
11 in SUMO2/3 (Fig. 5) (77). While SUMO2 and SUMO3 share this attachment consensus site,
11

the necessary sequence for conjugation is lacking within SUMO1 (58), enabling SUMO2/3
proteins to form and terminate chains in vitro and in vivo by the attachment of one SUMO
molecule to internal lysine residues of another SUMO moiety (58). One signaling process initiated
by SUMO chains is the evolutionarily conserved SUMO-targeted Ubiquitin ligase (StUbL)
pathway in which poly and multi SUMOylated proteins, are recognized by E3 ubiquitin ligases
containing specific binding modules for these structures.

Figure 5- SUMO’s Characterized Functional Properties Affect Many Biological Processes
SUMO2/3 proteins can form chains to each other or substrates at lysine 11 in different conformations to aid in
specific cellular processes such as protein trafficking, chromatin regulation, stress response, cell cycle
progression and genome stability.

Such is the case for the RING-type ubiquitin ligases that can also synthesize hybrid SUMOubiquitin chains by ubiquitylating lysine residues on SUMO. Tryptic digests and MALDI-TOF
mass spectrometry analysis of SUMO2 conjugation assays show that this self-conjugation occurs
via Lys11 that exists within a SUMO modification motif (78). Moreover, mutation of lysine 11 in
SUMO2 and SUMO3 blocks the assembly of polymeric chains in reactions either lacking or in the
presence of substrate (78). As mentioned earlier, while SUMO2 and SUMO3 are 96% identical,
12

these studies postulate SUMO2 is the better substrate for chain formation than does SUMO3, thus
the 3-amino acid variance in the N-terminal region functions to partially inhibit the conjugation of
SUMO3 (78). However, whether this inhibition is due to different secondary structures of the two
modifiers in this region, the disruption of specific amino acid interactions with Ubc9, or if the
SUMO system has the capability of regulating itself remains to be determined.
The SUMO proteases also have preferential affinities for the diverse SUMO1/2/3 paralogs
(56). SENP1 and SENP2 can deconjugate all SUMO1-modified substrates with implications in the
hypoxic (79), androgen (80), and interleukin-6 (81) response arrangements. In contrast to SENP3,
SENP5, SENP6, and SENP7 all prefer SUMO2/3 as substrates (56). SENP6 and SENP7 also have
chain-editing activity, which removes SUMO2/3 from poly-SUMO chains often implicated in
homologous recombination (82, 83). In summary, although the enzymatic mechanism of
SUMOylation is like ubiquitination, their pathway enzymes perform in entirely distinct ways.
Moreover, while the SUMO enzymes are present at lower levels than their counterpart in the
ubiquitin pathway, the number of SUMO substrates remain vast. This then raises the question of
how does SUMOylation exactly achieve specificity through a limited number of conjugating and
deconjugating enzymes? Furthermore, how does such a minute amount of SUMOylation of a given
substrate lead to such amplificatory biological effects?
1.5 SUMO, The Regulator
Current mass-spectrometry experiments posit that as many as, if not more, 6000 proteins are
SUMOylated (84). Many of these substrates have been implicated in crucial physiological
processes, such as early embryonic death in mice due to mitotic defects because of Ubc9
knockdowns (85, 86). A very well-characterized role for SUMOylation in cellular health is the
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repair of DNA breaks. Protein SUMOylation occurs at the lesion sites to recruit the E3 ligase that
further aids the stabilization of protein/protein interactions within the supramolecular complexes
responsible for DNA repair (87). Finally, further recruitment of SUMO-binding proteins such as
the SUMO-targeted Ubiquitin Ligase RNF4 occurs who then bind to MDC1, a mediator of DNA
damage checkpoint 1, which becomes ubiquitinated to signal it for degradation thus finalizing an
efficient repair illuminating a complex orchestrated pathway carried out by the Ubiquitin-like
family for carrying out and regulating cellular processes (87).
The other best-studied cellular function that is widely controlled by SUMOylation is
transcription (88-90). The initiation of transcription is crucial to regulating gene expression and is
a collaborative effort between the structural properties of DNA and specific transcription factors
(91). Transcription factors are essential regulatory proteins that affect gene expression by binding
to exposed DNA sequences. SUMOylation plays an extensive role in gene regulation considering
the sizeable amount of SUMO conjugate targets is transcription factors. While these transcription
factors symbolize a major group of proteins regulated by SUMO modification (92), the blocking
of SUMOylation modification on gene-specific transcription factors ELK-1 (93), C/EBP (94), cJun (95), generates an increased amount of transcription on target genes. However, gene-specific
transcription factors are not the sole SUMO targets, recent wide-range proteomic reports have also
cataloged general transcription machinery including multiple transcription factor subunits as other
SUMO foci such as TFIIA, TFIIF, TFIID, TBP, several TATA-binding protein factors, and more
notably subunits of RNA polymerase II (96). While these previous studies demonstrate a strong
SUMO connection with transcriptional repression, others have shown SUMO is also existent at
transcriptionally active genes (65). Ultimately, a transcription complex is formed to facilitate the
binding and transcription by an RNA polymerase that can’t proceed with transcription without the
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factors such as activators, regulators, repressors, and enhancer sequences which have all been
implicated as substrates for SUMOylation (91) (97). Furthermore, even when transcription factors
are present in a cell, transcription does not always occur- because often, the transcription factors
cannot reach their target sequences.
Chromatin complexes result from the magnetism of the negatively charged DNA to positively
charged histones arrangements into nucleosomes and must be unwound for expression. Thus, the
state of chromatin is a major player in gene expression because it limits the entry of transcription
factors and RNA polymerase into the DNA double helix (91). These chromatic arrangements
ultimately reflect a restrictive ground state of a gene’s expression serving as a means for allowing
the concurrent regulation of functionally and/or structurally related genes that also contributes to
the shifting levels of intricacy in gene regulation (98). Further findings postulate observations of
transcriptional co-repressors, HDACs, preferentially bind to SUMOylated transcription factors
(99). Interestingly it was reported that reducing SUMOylation at the induced ARG1 promoter, a
critical gene for tissue repair in M2 macrophages, hinders the cell’s ability to stop transcription
upon activating the signal disappearance (100). This illustrates a complex inverse mechanism
indicating while SUMO is upregulated upon the induction of active genes, modification occurs at
the promoters but regulates transcription levels by aiding in switching off the transcription (65).
Once the helical orientation of DNA is unwound, the sequence functions as the archetype for
complementary base-pairing transcribed by RNA polymerase II, the enzyme responsible for
catalyzing the configuration of a pre-mRNA molecule (101). Genome-wide analysis of SUMO1
conjugation to chromatin-associated proteins revealed a striking enrichment of the SUMO1 mark
on exons and no enrichment on introns (102). The mechanism in which the exons are recognized
at the DNA level, however, is unclear. It is therefore likely that the SUMO1-conjugated proteins
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associated with exons may act as splicing factors (103). It is known that overall splicing patterns
are sensitive to changes in specific splicing factors upon deviations from normal environmental
conditions, causing swift genome-wide splicing profiles that are unique to the stimuli (104, 105).
This introduces an intriguing model with responses to environmental changes, prompt posttranslational modifications adjust precise splicing factors to control their roles in the excision of
specific introns (106). Due to its large size, the spliceosome encompasses both cis-elements that
directly interact with the nucleic material, as well as trans-acting elements acting directly on the
cis-acting proteins. Although the RNA is not in direct contact, the trans-acting elements control
the arrangement of the cis-acting elements such as the snRNPs: U1 and U2 (107). Proteomic
methods revealed RNA-related proteins are the principal group among SUMO substrates as well
as essential splicing proteins: U2 snRNPs that aid in the pre-mRNA branch site recruitment at the
donor splice site, the U4/U6 proteins required for tri-snRNP formation, the functionally important
U5 proteins, the RNA helicase required for spliceosome activation, and the catalytic core scaffold
proteins were all identified as SUMO substrates (108). Other proteomic studies have classified
SUMOylation targets in mRNA metabolism including capping, splicing, and polyadenylation
(109), as well as regulatory roles in RNA editing/binding by hnRNPs (110). Essential splicing
factors, such as serine-arginine rich (SR) proteins have been identified as SUMO substrates (111).
The SR protein SF2/ASF interacts with UBC9 and enhances SUMOylation of specific substrates
as well as promotes SUMO conjugation to RNA processing factors (111). SR proteins ensure the
coupling of splicing to transcription as they are recruited together with U1 snRNP by RNA
polymerase II and co-transcriptionally deposited on the exons 5’ donor splice sites of nascent
transcripts (112). Another RNA editing enzyme, ADAR1, binds to double-stranded RNA and is
also modified by both SUMO1 and SUMO2, as well as containing capabilities of engaging as a
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polySUMO-modified protein (113). Ultimately, SUMO modification edits activity by repressing
the dimerization domain of the protein, demonstrating its role in regulating the RNA editing (114).
Thus, the splicing of the primary SUMO1/2/3 transcripts may serve as an important regulatory
mechanism, and if splicing can be regulated then it may serve as a potential target for drug therapy.
1.6 SUMOylation and Disease
The SUMOylation system has profound effects on many pathophysiological processes such as
cancer,

diabetes,

heart

failure,

autoimmune

diseases,

and

neurological

disorders.

The deregulation of both the SUMO ligases and de-conjugation enzymes have been linked to
cancer pathogenesis as well as response therapies which is accredited to the delicate homeostasis
of the SUMO1/2/3 proteins involved in DNA repair, cell division, and cellular signaling in
normally dividing cells (115). A prime instance of this occurs upon Acute Promyelocytic
Leukemias (APL) where SUMOylation inhibition of the PML-RARα fusion oncoprotein is
prompted by arsenic trioxide, a therapeutic treatment in conjunction with retinoic acid (116). An
analogous circumstance ensues for arsenic-induced SUMO-dependent deprivation of the human
T-cell lymphotropic virus type I (HTLV1) viral protein associated with Adult T-cell
Leukemogenesis (117). Furthermore, SUMOylation also partakes in Acute Myeloid Leukemia
(AML) therapy responses through its facility to regulate gene expression (118).
The SUMOylation pathway enzymes are overexpressed in Multiple Myeloma which results in
a reduced response to melphalan-based chemotherapies (119-121). This dysregulation of SUMO
enzymes is also seen in microphthalmia-associated transcription factor (E318K) which is not only
associated with melanoma but also with renal cell carcinoma (122). Genome-wide shRNA
screenings classified SUMO E1 and E2 conjugating enzymes as KRAS synthetic lethal partners,
however, this was dependent only on SUMO1, not SUMO2/3 modification (123). Similar
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screenings of Myc-driven tumors identified a component of the SUMO E1 ligase, SAE2, as the
most substantial artificial lethal partner owed to the SUMOylation requisite for proteins involved
in the formation of the mitotic spindle (122). Moreover, in human breast cancer tumors with
abnormal Myc levels, low SAE1 and SAE2 conjugation were linked with longer metastasis-free
survival (122). Thus, targeting the SUMO pathway in conjunction with recently discovered
pharmacological inhibitors and current therapies could potentially represent a potent stratagem to
improve the outcome of patients (5).
1.7 SUMOylation and the Cellular Stress Response
The SUMOylation system also has immense roles on cellular stress impressions such as the heat
shock response, a transcriptional platform to offset protein homeostasis imbalances orchestrated
by Heat Shock Transcription Factor 1 (Hsf1) (124). Post-translational modifications, particularly
phosphorylation at multiple sites, are one of the vital mechanisms proposed for the adaptation of
Hsf1 activity to the needs of individual cells (124). However, according to more recent proteomics
data, Hsf1 is also modified by SUMO at several sites resulting in rapid conjugation of SUMO2
and SUMO3 to protein substrates (125, 126). This morphological modification is postulated to
provide prompt protection of partially misfolded proteins by increasing their solubility through the
addition of SUMO2/3 chains (127). Consistently, cells depleted for SUMO2/3 are more sensitive
to the heat stress (128). While heat stress has been proven to upregulate a global increase in SUMO
conjugation, this also concurrently leads to SUMO deconjugation of specific proteins (128).
However, this is not always true because SUMO also activates transcription factors HSF1 and HSF2

SUMOylation which elevates their DNA binding activity causing an increase in expression,
therefore providing more protection against protein-damaging stress (128).
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To further indulge on SUMOs role in the cellular stress response, the promoter region of
the SENP1(SUMO protease) gene contains androgen (hormone response element receptor
signaling) and hypoxia response elements (79). Oxygen deprivation elevates SENP1 transcription
(now identified as a hypoxic-response gene in humans) via HIF-1α dependent pathways increases
levels of SENP1 protein levels in hippocampal neurons via attachment of SUMO peptides to
promote association with interacting proteins, or conversely, the SUMO moiety inhibits
interactions by blocking the sites (129, 130). One candidate capable of coordinating the
multimodal molecular mechanisms that underlie the cytoprotection induced in the brain as a
consequence of cooling is that of global SUMOylation (131) who previously reported on the
The cellular SUMOylation system has been established as an essential factor for the Influenza
A life cycle for viral replication regulation and gene expression during infection. Due to their way
of replication and a fragmented genome, Influenza viruses mutate quickly often undergoing
antigenic shift rendering seasonal vaccines useless with and sometimes even without the antigenic
shifts. Our laboratory has not only shown that several influenza viral proteins namely: NS1, PB1,
NP and M1 are modified and regulated by the host cell’s SUMOylation machinery (2), but also
large increases in global cellular SUMOylation can obstruct the expression of the late influenza
gene, M1(Rosas-Acosta, manuscript under review). Animal studies in which mutagenic mice
containing SUMO1/2/3 knockouts were infected with WSN Influenza showed dramatic lethality
in the alveolar tissue surrounding the lungs not only causing dramatic morphological differences
but functional differences as well (Rosas-Acosta manuscript under review). In total, increases in
cellular SUMOylation may play a protective role during influenza infection implied by the inverse
relationship between the virus’ ability to increase SUMOylation and pathogenicity. It is therefore

19

critical to consider broad-spectrum therapies employing diverse approaches to fight infections of
this sort, for example by targeting the different cellular systems crucial for viral multiplication.
Although our lab’s previous data clearly identifies the viral components responsible for
triggering GICS during influenza infection, the molecular mechanisms that mediate the net
increase in total SUMO modifiers required to allow global increases in cellular SUMOylation are
far from clear. Thus, a better understanding of the changes in global SUMOylation occurring
during infection and their correlation with viral infection progression could lead to
molecules/compounds that modulate the cellular SUMO system and could provide potentially
effective Influenza antivirals as well as cellular level insult therapies. The relevance of our
laboratories findings indicates potential increases in cellular SUMOylation may play a protective
role by other types of stress including oxygen and glucose deprivation (OGD) (3),
hypo/hyperthermia (4), and cancer (5).
1.8 SUMOylation Regulation
While the SUMOylation system has a far reach into both normal cellular physiological processes
as well as stress responses, very little is known about how the SUMOylation system itself is
regulated. Given the numerous potential applications for disease it is therefore critical to develop
a deeper molecular understanding with a further goal to artificially manipulate the SUMO system
for therapeutic purposes. One candidate for SUMOylation regulation is SRSF1, a prototypical SR
protein, with roles in constitutive and alternative splicing (132), is implicated in nonsensemediated mRNA decay (133), mRNA export (134), translation (135), and recently reported as a
modulator of protein SUMOylation, by connection with Ubc9 to enhance SUMOylation of specific
targets (136). SRSF1 also contributes regulatory functions in heat-shock-induced SUMOylation
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by promoting SUMO conjugation to RNA-processing factors (137), as well as assisting in PIAS1
(protein inhibitor of activated STAT1) regulation, provoking PIAS1-induced overall protein
SUMOylation. It should be noted, PIAS1 can be found co-localized with other SUMO targets in
nuclear bodies with the E3 ligase conjugating enzyme of the SUMO pathway, components of premRNA splicing factors, and the RNA processing machinery (138).
Regulation of SUMOylation through target modification has also been posited to occur on
SUMO substrates that can enhance or block SUMOylation. Competition with other lysine-directed
modifications such as ubiquitination of acetylation substrates can abolish SUMOylation while
phosphorylation has the potential to act as both a positive and a negative regulator (139). Enhanced
SUMOylation has been documented upon phosphorylation of specific residues that are attached to
branched SUMO acceptor sites also previously referred to as Phosphorylation Dependent SUMO
Motifs (PDSM) (139). In addition to these outcomes, the ascertainment of SUMO isopeptidases
with seemingly contrary specificities for SUMO1 and SUMO2/3 insinuates that the global
conjugation capacity of SUMO1 and SUMO2/3-modified proteins may, in fact, be regulated at the
level of removal rather than conjugation (140, 141). While little is comprehended about the
functional discrepancy of SUMO1 in contrast with SUMO2/3, the unearthing of SUMO2 and
SUMO3 multimers generates a novel dimension of complexity to SUMO conjugation
coordination. While SUMO2/3 chains habitually form in response to genotoxic or proteotoxic
stress and are preferentially linked via lysine 11 of SUMO2/3 (125), it was further reported that
K11 of SUMO2/3 undergoes reversible acetylation with SIRT1 being the K11 deacetylase in a
purified in vitro system (142). It was moreover reported that K11 acetyl mimicking SUMO2 did
not impact the StUbL pathway, signifying these non-canonical chains are more prevalent in cells
and shown to form under both basal and stress conditions using mass spectrophotometry-based
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SUMO proteomics (142). Thus, if acetylation of SUMO2/3 can impair chain formation and restrict
chain length this could serve as a potential regulator of the SUMO stress response (142).
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2. Aims
While substantial progress has been achieved in characterizing the functions and effects associated
with SUMO modification, our knowledge of the mechanisms regulating the activity of the
SUMOylation system remains limited. One area that remains unexplored is the potential
contribution that post-transcriptional processing may play in regulating cellular SUMOylation.
Therefore, a more detailed understanding of the molecular mechanisms contributing to SUMO
gene expression regulation is critical to achieving our long-term goal of using the cytoprotective
functions of the SUMO system to develop novel therapeutics against cellular stress. The
experiments proposed here will provide essential data on untapped areas of SUMO research and
could lead to the development of innovative approaches to combat influenza viral infections while
also improving patient outcomes following ischemic events. To test our hypothesis of alternative
splicing regulating the SUMO1/2/3 genes in the pursuit of the long-term goal, two specific aims
will be carried out:
Specific Aim 1: Measure Alternative Splicing Contribution in Cellular SUMO Level
Regulation. Evidence of alternative splice products for the SUMO1/2/3 genes indicates alternative
splicing may contribute to the regulation of SUMO levels in the cell. Thus, a core methodology
will be needed to quantify each variant within the cell by qRT-PCR.

Sub Aim 1.1: Establish the normal proportion of the different SUMO variants in the cell.
Total RNA will be purified from cells maintained under normal culture conditions and used to
perform qRT-PCR analyses to determine the abundance of each variant transcript for the
SUMO1/2/3 genes. To ensure a proper representation of various cell types, we will establish
these values for at least two different immortalized human cell lines as well as for peripheral
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blood mononuclear cells (PBMCs) derived from healthy donors. These cell lines were selected
because of their human origin, ease of growth, responsiveness to stress, ease of liposomemediated transient transfection, and their ability to support influenza virus multiplication.
Sub Aim 1.2: Observe if the copy number of each variant and its proportional abundance
to other variants are affected by stress. Once copy numbers/normal proportions for each
SUMO variant have been established, we will determine whether these values are affected by
stressors including heat-shock (43°C for 1 hour), influenza virus infection (Multiplicity of
Infection [MOI] of 10, 12-hour post-infection, and two different viral strains, A/WSN/1933
H1N1 and A/Memphis/31/1998 H3N2), and cold-shock (30°C for 16 hours). To ensure that
the stressors used are triggering the expected responses, each stress treatment will include the
quantitative assessment of a gene transcript known to be affected by the specific stress
condition being studied. Specifically, we will measure the transcript levels of HSP70 for heat
shock, Influenza gene segment M1 for H1N1 infection, and RBM3 for cold shock.
Specific Aim 2: Characterize Functional Properties of the SUMOα Isoforms. Based on the
quantitative assessments performed to date, out of all the SUMOα-coding variants the one coding
for SUMO3α appears to be by far the most abundant in proportion to its prototype as well as being
the only alternatively spliced variant with an intronic inclusion; we, therefore, hypothesize,
SUMO3α is likely to have the largest effect on cellular SUMOylation. According to informatic
prediction analyses, SUMO3α could also be relevant as it is predicted to have an extra intrinsically
disordered domain absent in the SUMO3 prototype protein. To characterize the functional
properties of the SUMOα isoforms, we will pursue the questions presented below.
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Sub Aim 2.1: Probe for translational implications of the SUMO1/2/3 variants. This will
be conducted through the fractionation of purified RNA in A549 and Hek293A cell lines under
both normal and cold shock conditions, deemed to be the one stress condition to have the
largest effect on all SUMO1/2/3 variants. The presence of all the SUMO1/2/3 variants in
cytosolic extracts could strongly indicate that all SUMOα isoforms (alternate spliced products)
are translated, thus justifying a further need for functional assessment.
Sub Aim 2.2: Describe conjugation abilities of SUMOα s in vivo. Overexpression of a Histagged form of SUMO1α in its processed form (with the diglycine motif at its C-end) by
transfection in HEK293A cells will be useful in determining if isoforms are conjugatable in
vivo. The use of an N- terminal His-tag allows sensitive detection of the protein using anti-His
antibodies, easy differentiation from the endogenous pool of SUMO proteins, and could allow
the proteomic identification of SUMOylated targets if any of the SUMOα were to be
conjugatable.
Sub Aim 2.3: Determine the SUMOα differences on cellular SUMO1/2/3 localization. If
our previous predicted results all hold true, then the final test in characterizing the
SUMO1/2/3α isoforms would be to determine differences in localization. This will be carried
out through the transfections using the respective SUMO1/2/3 His-S and YFP- tagged clones
in 96 well plates to use in fluorescence microscopy.
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3. Methods and Materials
3.1 Primer Design Approach
An overall map of the RNA-seq data obtained from the NCBI database was first constructed using
the SUMO1/2/3 genes and their respective alternative variant sequences to infer their distinctions.
The map was drawn based on a series of alignments performed by ClustalW between the full
genomic sequences for the SUMO1 gene located within Chromosome 2, the SUMO2 gene located
within chromosome 17, the SUMO3 gene located within chromosome 21, as well as the different
mature mRNA transcripts for all SUMO1/2/3 variants. Afterward, a more detailed map of each
transcript was assembled to focus on the boundaries between exons to simplify the design of
primers targeting exon/exon junctions. The primers used to quantify all different mature transcripts
were designed using the following guidelines: 1) Paired primers should have similar TMºs (melting
temperatures) 2) the expected PCR products produced should be between 200-300bp in length 3)
Primers should target exon/exon junctions 4) There should be specific primer sets for every mature
mRNA 5) Any given primer pair should not amplify more than one mature mRNA 6) Primers
should contain as close as possible 50:50 [GC] : [AT] content with no more than 40:60 content
either way 7) Primers should end on a “clamping sequence” (CG, GC, GG, CC) and lastly, 8)
primers should be free of sequences likely to form strong secondary structures. All primers were
ordered from IDT (integrated DNA technologies) and reconstituted in sterile TE at a 100μM
concentration. The 100μM primer stock solutions were further diluted down to 10μM in TE to
produce working for direct use in RT-PCR and qRT-PCR reactions.
3.2 Cell Culture
Human embryonic kidney cells (HEK293A) are a suitable cell model due to their ease of growth
and high transfection rates, while A549 cells are adenocarcinoma human alveolar basal epithelial
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cells are an ideal model that can form an abundance of intercellular connections. The A549 cell
lines are often used as an in vitro model for Type II pulmonary epithelial cell model in drug
metabolism assays but also serve as an efficient transfection host. To avoid the likelihood that our
data may be biased to events that are specific to immortalized cell lines, we included Peripheral
Blood Mononuclear Cells (PBMC) in our analyses. These cells include both lymphocytes (T cells,
B cells, NK cells) and monocytes and are obtained from healthy volunteers. HEK293A and A549
cells were grown in tissue culture in DMEM media containing 10% Fetal Bovine Serum, plated in
6-well plates at a concentration of 3x10! cells per well, and became confluent roughly 24-34 hours
post-plating. The A549 and HEK293A cell lines were collected in groups of 3 wells per each
sample for subsequent RNA purification. PBMCs were directly isolated from patients and stored
in cryovials awaiting RNA purification.
3.3 RNA Purification
Cells were washed in 1mL PBS and total RNA was purified using the Qiagen RNeasy Mini KitÒ
via the QiashredderÒ method. To begin, 200µL of buffer RLT was added to each well of a 6-well
plate containing approximately 1x10" cells per well; the resulting mix was incubated for five
minutes at 23°C. The lysates from each of the three wells were combined into a single well, thus
resulting in two samples of each cell line per plate. The samples were then transferred into a
microfuge tube containing a QiashredderÒ cartridge, mixed until there were no visible clumps,
and centrifuged at full speed for two minutes at 23°C. Afterward, one volume (roughly 600µL) of
70% ethanol (EtOH) was added to the lysate followed by careful pipette mixing to ensure proper
resuspension and homogenization of the lysate. Up to 700µL of each sample was added to an
RNeasyÒ spin column and centrifuged for thirty seconds at 8000 x g. The flow-through was
discarded and 700µL of Buffer RW1 was added to the RNeasy spin column, and again centrifuged
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for thirty seconds at a speed of 8000 x g and 23°C. Next, 500µL of Buffer RPE was added and
centrifuged for thirty seconds at 8000 x g and 23°C. Another 500µL of Buffer RPE was added but
centrifuged for two minutes at 8000 x g to dry the cartridge. Subsequently, the cartridge was placed
in a new 2mL collection tube and centrifuged for one minute at full speed, then placed into a new
1.5mL collection tube, and RNA was eluted in 50µL of RNase-free DEPC-treated H2O and
centrifuged for 1 minute at 8000 x g. The eluted RNA was finally then aliquoted in 9µL and stored
at -80ºC.
3.4 Assessment of Purified RNA Quality and Quantity
To assess the quantity of the purified RNA a Qubit Fluorometer 3.0Ò was used and formaldehydeagarose gel electrophoresis was used to determine the quality of the RNA obtained, according to
the following procedure: 10xFA gel buffer (consisting of 200mM 3-N-morpholino propane
sulfonic acid (MOPS), 50mM Sodium Acetate, and 10mM EDTA), the pH was then adjusted to
7.0 using 68mL of 1M-NaOH per one liter of 10x FA Buffer. 1xFA gel running buffer was then
be made using 100mL of the 10xFA gel buffer previously described, 74mL of 10% Formaldehyde
and 826mL of DEPC-H20. To load the gel while ensuring proper loading of the total purified RNA
samples, we made a 4xRNA loading buffer consisting of 20µL saturated bromophenol blue, 800µL
of 500mM EDTA, pH 8.0, 2.664mL of 10% Formaldehyde, 2mL of 100% glycerol, 3,080 mL
formamide, 4mL of 10xFA gel buffer and lastly 656µL of DEPC-H20. To produce an FA gel mix,
we mixed 3.6g Agarose, 30mL 10xFA gel buffer, and 280mL of DEPC-H20. The contents were
then heated up to a boil and the agarose was allowed to solubilize by cooling to 65°C. 20mL of
10% Formaldehyde was added to the mixture and finally stored at 65°C. It should be noted that
problems arose using DEPC-H20 in both gel electrophoresis and qPCR reactions, we then
switched to using QH20. Qubit Fluorometer quantification began by initially making two standards
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that generate a curve for the purified RNA to measure against. A working solution must first be
made for both standards and samples by using 199µL of Qubit buffer with 1µL of Qubit Reagent.
Both standard one and standard two use 190µL of the working solution combined with 10uL of
Standard 1 and Standard 2. Once the standards were properly vortexed for two to three seconds,
the samples must sit for two minutes before the reading commences. To begin the assembly of
reading the actual samples, 198µL of the working solution is combined with 2µL of the purified
RNA followed by the mixing and settling of the samples.
3.5 cDNA Synthesis
Following the purified RNA extraction from both HEK293A and A549 cell lines, cDNA synthesis
was performed using an NEB-M-MuLvÒ kit. This system required a total of 2µg of RNA added
to 2µL of 50mM Poly-T primer, 1µL of 10mM dNTPs, and lastly qH20 to bring the reaction
volume up to 10µL. The reaction was then heated for five minutes at 65°C and kept on ice while
the other components were added: .5µL RNAse inhibitor, 2µL 10x M-MuLv Buffer, 1µL M-MuLv
Reverse transcriptase, and lastly qH20 to bring the reaction volume up to 20µL. The final steps of
the cDNA synthesis included incubations at 42°C for one hour, followed by a cool down to 4°C.
Negative control samples were produced using all the ingredients minus the Poly-T enzyme and
the Reverse transcriptase, qH20 was used in place of these components for the negative control
reactions.
3.6 qRT-PCR
To perform the initial PCR reactions, the Bio-Rad iTaq™ Universal SYBR® Green One-Step Kit
was used completely avoiding the need to synthesize cDNA altogether. Instead of using the typical
2ug of RNA, this new method was able to carry out the reactions with a mere 100ng RNA coupled
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with 10uL reaction mix, 2uL of both forward and reverse primers, .5µL of reverse transcriptase,
and lastly, water to bring the reaction volume up to 20µL. Negative controls were assembled using
all components minus RNA template. Subsequent runs were carried out using a MyGo
thermocycler, along with MyGo programming ran on MAC software.
3.7 Cloning of SUMO1/2/3 Variants
Clones of each of the SUMO1/2/3 variants were generated first by using a Taq Polymerase PCR
reaction whose products were necessary to ultimately produce calibration curves in hopes of
detecting the exact copy number of each of the SUMO1/2/3 variants produced within the cell. The
PCR reaction consisted of 5µL cDNA, 2.5µL 10mM DNTP, 5µL Q5 High-Fidelity Buffer, 2µL
of each primer, 1µL of Q5 High-Fidelity DNA polymerase, and 32.5µL QH20 to bring the reaction
volume up to 50µL. The PCR products generated were then added to a Thermo-Scientific
CloneJET PCR Cloning KitÒ: 10µL of 2x Reaction Buffer, 1µL of each PCR product, and 7µL
of QH20 for a total of an 18µL reaction volume. The reaction was then vortexed briefly and
centrifuged for three to five seconds, followed by incubation at 70°C for five minutes. Finally,
ligation reactions were compiled on ice by adding 1µL of the pJET1.2/blunt cloning vectorÒ and
1µL of T4 DNA ligase to the 18µL blunt-end restriction digest reactions.
3.8 Transformation of SUMO1/2/3 Clones into NEB 10-Beta Competent E. Coli
Upon the ligation reaction setup, the transformation of NEB 10-beta competent E. coli cells was
then necessary. The transformation entailed thawing of the cells on ice for ten minutes followed
by splitting the cell mixture into 2x 25µL aliquots. From this reaction, 1.5µL of each ligation
reaction was then added to the cell mixture, carefully mixed, and incubated on ice for thirty
minutes. Heat shock was performed for exactly thirty seconds at 42°C and the samples were then
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placed on ice again for five minutes. The NEB 10-beta/ Stable Outgrowth Media (SOC) was added
to the mixture (450µL) and incubated at 37°C for sixty minutes at 250rpm. Two different volumes
of each SUMO1/2/3 variant mixtures were plated (75µL and 300µL, respectively) on 2xYT- Agar
plates and incubated overnight at 37°C. To screen for the colonies with the correct SUMO1/2/3
variant sequences, a P200 pipette tip was used to pick five colonies of each variant and placed into
300µL of H20. Of the 300µL bacterial solution: 5µL was used to set up a replication plate, and
another 5µL was used to set up another Taq Polymerase PCR reaction (Figure 7) for the screening
process along with 2.5µL dNTP, 5µL Taq Polymerase Buffer, 2µL of the forward primer provided
by the CloneJET PCR Cloning Kit, 2µL of the respective SUMO12/3 variant reverse primers, 1µL
Taq Polymerase and 32.5µL of QH20.
3.9 Maxi- Prep Procedures
Sequence samples were then subjected to Maxi-Prep procedures using a ZymoPURE II Plasmid
Maxi Prep kit to continue with the goal of producing the respective SUMO1/2/3 variant calibration
curves. The maxi-prep protocol began with the inoculation of the three selected sequenced samples
initially stored in cryovials (-80°C) into 500uL 2xYT. The bacterial cells were then harvested by
centrifugation at 3400 x g for ten minutes at 4°C. The supernatant was pipetted out and 14mL of
ZymoPure P1 containing RNAse A as well as LyseBlue was added to the pellet followed by
complete mixing until no cell clumps remained. 14mL of Buffer P2 was then added and mixed
thoroughly by inverting the sealed tube six times and incubated at room temperature for 3 minutes.
14mL of chilled buffer P3 was added to the lysate and mixed immediately by inverting four to six
times. The lysate was loaded into the ZymoPURE Syringe Filter followed by a 5-minute incubation
allowing precipitation to float to the top. The syringe was then added into a clean 50mL conical
tube and pushed through until 35mL of the cleared lysate was recovered. 14mL of Binding Buffer
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was added to the cleared lysate and mixed thoroughly by inversion 10 times. The mixture was then
added to a Zymo-Spon V-P Column Assembly and vacuumed until all liquid had passed. 5mL of
Wash 1 was added and vacuumed. 5mL of wash 2 was added and repeated once more. The samples
were then centrifuged at 10,000 g for 1 minute. The columns were then transferred to a clean
1.5mL microfuge tube with 400ul of elution buffer added directly to the column matrix. The
samples were incubated for 2 minutes and centrifuged at 10,000 g for 1 minute. Lastly, for Endo
Zero Plasmid DNA, a final spin was conducted. The maxi-prep samples were quantified using a
Qubit Fluorometer and calculations were performed to measure precisely 1ug/µL of each of the
SUMO1/2/3 variants plasmid DNA.
3.10

T7 RNA Polymerase In Vivo Transcription

Using a Mega script RNA synthesis kit, it was necessary to generate an in vivo transcription using
the plasmid DNA of each SUMO1/2/3 variant beginning with a HindIII restriction digest, an
enzyme that doesn’t cut SUMO itself but only has a cut site within the plasmid itself. This 50µL
reaction resulted in 5µL being used for quality verification by gel electrophoresis, and the rest
precipitated by adding 4.5µL Ammonium Acetate and 90µL of chilled 100% EtOH. The SUMO
variant samples were centrifuged for thirty minutes at full speed and the pellet was re-suspended
in 20µL of sterile TE. The precipitated DNA was quantified again using the Qubit to ensure exactly
1µg of DNA would be used for the following in vitro transcription which consisted of assembling
an NTP mixture (2µL of each), 2µL of 10X Reaction Buffer, 2µL of enzyme mix, and the
respective SUMO1 variant 1ug amount at 23°C. The mixes were then incubated for four hours at
37°C and subjected again to gel electrophoresis to ensure the proper product sizes.
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3.11

Generating Calibration Curves

Calibration curves were necessary to obtain an exact copy number of each SUMO1/2/3 transcript
within the cell to measure true fluctuations upon different stress conditions. To begin, the
sequences for each of the SUMO1/2/3 variants were mapped out and inserted into the pJET1.2
plasmid sequence in between the T7 promoter site and the HindII cut site (AAGCTT). The exact
number of nucleotides was entered into an oligonucleotide calculator to determine the exact
grams/mol of each transcript. The transcript weight was then multiplied by 10## (initial copy
number dilution) and divided by Avogadro’s number (6.02 x 10$% molecules) to generate the
needed amount of transcribed RNA in nanograms based on the molecular weight of each
SUMO1/2/3 gene variant transcript. Based on the nanogram amount required for each RNA
sample, dilutions were made following the initial Qubit quantifications. From the first dilution
which contained 10## copies, serial dilutions loading 10uL of each previous dilution were
performed all the way down to 10& copies serving as a negative control. The concentration of the
SUMO1/2/3 variants transcribed RNA was the amount of each serial dilution loaded into
subsequent qRT-PCR triplicate reactions using the one-step method. However, the qRT-PCR
reactions started with the 10' copy number dilution all the way down to 10& serial dilutions being
loaded. Statistical analysis involved using the Cq values ran in triplicates with R-values calculated
and compared amongst each other using excel spreadsheets.

3.12

Stress Treatments

Cells plated in 6-wells at a concentration of 3x10! cells per well demonstrated proper confluency
36 hours post-plating. Stressors include heat shock (43°C for 1h), influenza virus infection
(Multiplicity of Infection [MOI] of 10, 12h post-infection with the viral strain
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(A/Memphis/31/1998 H3N2), and cold shock (27°C for 24h) were all conducted three separate
times and collected for subsequent RNA purification beginning with lysis buffer also placed in
respective treatments to prevent the least amount of change to the cells post-treatment. To ensure
all stressors triggered the expected cellular responses, each stress treatment consisted of also
quantifying a gene transcript known to be affected by the specific stress condition being studied.
Specifically, the transcript levels of Hsp70 (heat shock), Influenza M1 (influenza infection), and
Rbm3 (cold shock). Additionally, to verify that the cellular stressor triggered the expected change
in global cellular SUMOylation levels, a set of examples exposed to identical stress conditions will
also be collected for immunoblot analyses using anti-SUMO and anti-GAPDH antibodies.
3.13

Nuclear vs Cytosolic Fractionation

Media was aspirated and the cellular monolayer was washed with 2mL of PBS. 200ul of ice-cold
Lysis Buffer J directly to the culture plate. Cell lysis was carried out by gently tapping the culture
dish and swirling the buffer around the plate surface for five mins while keeping the cell culture
plate on ice. Using a pipette, the lysate was transferred to an RNase-free microcentrifuge tube and
centrifuged for 10 minutes at maximum speed. Using a pipette with a small tup, transfer the
supernatant containing cytoplasmic RNA to another RNAse-free tube. The nuclear pellet was
obtained and mixed into 400ul of Buffer SK while the cytoplasmic fraction was mixed into 200ul
SK. A 200ul of 100% ethanol was then added to each respective fraction, transferred into a spin
column, and centrifuged for 1 minute at 3500 g and the flow-through was discarded. The columns
were then washed with 400ul of Wash Solution A to the column and centrifuged for 1 minute with
the flow-through being discarded and repeated three times. The columns were then centrifuged for
an additional 2 minutes to thoroughly dry the resin. The columns were then placed into fresh tubes
and eluted in 50ul of Elution Buffer E. The samples were spun down for 2 minutes at 200 g
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followed by 1 minute at 14000 g. Lastly, the samples were stored at -80C awaiting qRT-PCR ran
in triplicate using 100ng of mRNA. To calculate the % of RNA in each fraction, we began by
calculating the change in ΔCT through the subtraction of the CT for the highest minus CT for the
lowest. The fold difference was then calculated by2()* . Then calculate A: % for the one present
in the lowest amount 100/ (fold difference + 1). Then calculate B: 100-A. Check calculations by
A*FD=B.
3.14

His-Tag SUMO1/2/3 Plasmid Cloning

To assess whether SUMO1/2/3α can be processed to their GG-C end mature forms in vivo, we
over-expressed the His-tagged SUMO1/2/3α by transfection by using constructs coding for a Cterminal extension. The C-terminal extension adds 39 amino acid residues, including two T7 tag
epitopes, after the diglycine motif to allow rapid differentiation of the mature and precursor forms
by immunoblotting analysis of whole-cell extracts using anti-His and anti-T7 antibodies. The
cones were then transformed into E. Coli and screened for colonies using RT-PCR followed by a
BamHI digestion. Upon sequence confirmation, the samples were then mini prepped to amplify
DNA quantity and ready for transfections followed by immuno-blotting.
3.15

Transfections

Cells were plated at a low density of 2 x 10^4 and observed for 70% confluence. At the time of
this targeted confluence, remove the media from the wells and wash 2x w/2mL PBS. Aspirate PBS
and add 500uL of pre-warmed Opti-MEM per well and incubate at 37C, 5% CO2. Prepare
transfectant as follows: Label a tube as Trans-IT Master Mix. (Ensure this tube can hold 250uL x
Number of Wells). Add (250uL x Number of Wells) of prewarmed Opti-MEM into this tube. Add
7.5uL of Lipofectamine 2000 per well into this tube. Vortex the tube and incubate at room
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temperature for 10 minutes. Create a tube per well. Add 250uL of pre-warmed Opti-MEM into
each tube. Add the respective DNA to each of these tubes; 5ug/well. Add 250uL from the Master
Mix to each of the labeled tubes containing DNA carefully avoiding cross-contamination between
respective tubes. Vortex each tube for about 15 seconds and incubate at RT for 30 minutes. After
the liposome incubation, add transfectant into each well “dropper-style”. Let incubate for 3 hours,
after this incubation, add 1mL of complete media into each well.
3.16

Western Blot Analyses

Treated cells were lysed using boiling 500ul of 4x Laemmli Sample Buffer, passed through a
syringe twenty times to ensure DNA was sheared and 40ul of B-Mercaptoethanol was added
followed by one last boil for 3 minutes. Once sample preparation was complete, the samples were
run on a 10% SDS-Page gel using Bio-Rad System at 50V overnight. A large wet transfer unit was
then set up and ran for 3 hours using Bio-Rad System and the membrane was dried for 10 minutes.
The PVDF membrane was re-wet by soaking in 5mL of absolute methanol for 1 minute, discarded,
and rehydrated in QH20 by shaking for two minutes. The water was discarded, replaced, and shook
for another 2 minutes at room temperature. The membranes were then washed for 2 minutes three
times with 1x PBS at room temperature on a rocker. Lastly, the membrane was blocked by adding
10mL Licor Blocking Buffer for 60 minutes. Primary antibodies were added in solution with 100ul
of 10% Tween-20 to 10mL Blocking Buffer and mixed well. Primary incubated overnight at 4C
on a rocker, washed 5 minutes 3 times with 40mL 1xPBS + 0.05% Tween-20. Secondary
antibodies were added in solution with 100ul of 10% Tween-20 to 10mL Blocking Buffer and
mixed well. The secondary was left to incubate at room temperature for 1 hour, washed 5 minutes
3 times with 40mL 1xPBS + 0.05% Tween-20 followed by one final wash with 1xPBS.
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3.17

Confocal Microscopy

Hek293A cells were transfected and fixed with Hoechst 33342 staining solution for deep nuclei
visualization on the 460-490 nm channel in a 96-well plate with the generated SUMO1/2/3 and
SUMO1/2/3α His-tagged and YFP-tagged clones using the above-mentioned transfection
protocol. Upon the desired observed confluence, the cells were subjected to fluorescence confocal
microscopy with detection of the YFP-fusions of SUMO on the green channel, phalloidin to detect
actin filaments on the red channel, and DAPI to stain for DNA from three representative fields of
cells.
3.18

Tertiary Structure Prediction Analyses

An important tool for structural differences used in these studies was RaptorX prediction software.
RaptorX is a homology-based prediction software based on the structural properties of a protein
sequence without using any templates. Although it is sometimes considered fast and sloppy, it
outperforms other servers, especially for proteins without close homologs or with very sparse
sequence profiles (143). Quantitative measurements predict an∼84% Q3 accuracy for 3-state SS,
∼72% Q8 accuracy for 8-state SS, ∼66% Q3 accuracy for 3-state solvent accessibility, and ∼0.89
area under the ROC curve for the disorder prediction (143). However, this template-based
modeling doesn’t answer how and why proteins adopt their specific structures; and if structural
homologs do not exist or cannot be identified, models then must be constructed from scratch. This
procedure, called ab initio modeling, is essential for a complete solution to this problem; and can
help us understand the physicochemical principle of how proteins fold in nature (144). Currently,
the accuracy of ab initio modeling is low, and the success is generally limited to small proteins
(<120 residues). A more recent innovative approach to protein prediction structures is Alpha Fold
which is an artificial intelligence program developed with a system of subnetworks coupled
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together into a single differentiable end-to-end model based on pattern recognition. All six amino
acid sequences coding for the prototype SUMO1/2/3 proteins and their encoded isoforms were
entered in both the RaptorX and Alpha-Fold working notebook prediction servers to generate the
respective alignments of each SUMO paralog group. The scripts were then run in each respective
server to generate the tertiary structure of each SUMO protein of interest which were then
compared resulting in no apparent structural differences between the servers. For these studies, the
Alpha-Fold predictions were chosen.
3.19

Statistical Reports

To estimate the CNest (copy number estimates) using a linear regression analysis based on the
average CQ values of each variant and was applied under various experiments (H1N1, Cold Shock,
Heat Shock). The copy number was then calculated by taking 10^”ge/ul”. The average comparison
across positive and negative treatments were compared using an unpaired students t-test. A
Bonferroni correction was used to adjust for the number of multiple comparisons within each
treatment (sig: p<0.008). Nuclear and Cytosolic cellular fractions were compared using the log2
scale of the 2-∆CT method. Analysis was conducted using Stata v.17 and GraphPad Prism V.6.0.

38

4. Results
The extensive RNA sequencing data in the NCBI server has made it possible to catalog virtually
all mature mRNA transcripts present within a given organism thus facilitating our investigation of
the regulation of the SUMOylation system. ClustalW alignments of H. sapiens SUMO1/2/3
mRNA sequences obtained from the NCBI database indicate there are three different forms of
mature mRNA transcripts for SUMO1 (Fig. 6); variant1 (S1var1) contains all exons while variant2
(S1var2) undergoes a splicing event which is proposed here to correspond to a cryptic intron that
is eliminated in exon 5. However, due to this cryptic introns’ location within the 5’UTR, both
SUMO1var1 and SUMO1var2 transcripts code for what is considered the prototypical SUMO1
protein. SUMO1var3 is of particular interest because the second exon is spliced out, thus the
mature mRNA codes for a substantially shorter version of the protein here referred to as SUMO1α
with a 2.7kDa size difference compared to the familiar SUMO1 prototype protein. Both SUMO2
and SUMO3 also contain alternatively spliced transcripts, each of which has two variants, one
corresponding to the normally spliced transcript and one corresponding to an alternatively spliced
one: SUMO2α and SUMO3α (Fig. 6). In the case of SUMO2, the alternatively spliced transcript
completely skips exon 3 thus coding for a shorter protein isoform with a 2.8kDa difference in size.
Similarly, SUMO3 also contains two distinct transcripts, however, instead of deletion, SUMO3 is
the only SUMO gene with an intronic inclusion to the second exon coding for a larger protein
weighing 4.2kDa more than its respective prototype. It is proposed here that exon 2 of the
SUMO3var2 transcript likely contains a weak splicing donor that is sometimes ignored, leading to
the retention of a small fragment of the intronic sequence between exon2 and exon 3.
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Figure 6- SUMO1/2/3 Alternatively Spliced mRNA Transcripts Informatic Predicted Properties
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A: SUMO1 variants, denoted here SUMO1var1/2/3. SUMO1var1/2 code for prototype SUMO proteins
weighing 11.5kDa, although they have different exon5 splicing. SUMO1var3 lacks exon2, coding for a truncated
protein, SUMO1α (8.8kDa). SUMO2 variants, denoted here SUMO2var1/2. SUMO2var1 translates into
SUMO2 prototype (10.9 kDa). SUMO2var2 lacks Exon3 and codes for a truncated protein, SUMO2α (8.1 kDa).
SUMO3 variants, denoted here SUMO3var1/2. SUMO1var1 codes for prototype weighing 11.6 kDa.
SUMO3var2 is the only SUMO variant that contains an intronic inclusion in Exon2 and codes for a larger protein,
SUMO3α (15.8 kDa). E: Exon. The thin lines connecting the exons represent introns, the thick black lines
represent the SUMO genes, and the numbers underneath indicate base pairs from the transcriptional start of the
gene. V= variant. In every case, V1 corresponds to the normally spliced transcript.
B: JASSA SUMOylation motif predictor shows all SUMO1/2/3 amino acid sequence alignments indicating
SUMO1 and SUMO1α have an amino acid difference of 25 residues resulting in a 75.2% sequence similarity.
The skipping of exon 2 to generate the truncated SUMO1α protein is also lacking 5 Lysine residues at positions:
7, 16, 17, 23, and 25. SUMO2 and SUMO2α differ by 24 residues resulting in a 74.7% sequence similarity.
SUMO3 and SUMO3α have the biggest difference of 33 residues with a 73% sequence similarity.
C: Table summarizing the differences between the prototype SUMOs and their respective isoforms.

Informatic alignments using JASSA (Joined Advanced SUMOylation Site and Sim
Analyzer) were conducted to further assess the properties of these alternatively spliced isoforms
of the SUMO1/2/3 proteins. JASSA is an online predictor that incorporates a scoring system based
on a specific position frequency matrix generated from the positions of experimental
SUMOylation sites to predict if these isoforms contain functional properties at the amino acid level
(145). Corresponding with different web tools, JASSA exhibits superior executions owed to
applied innovative qualities concerning improved evaluations of the extrapolation. These
improvements consist of recognizing database hits that are equivalent to the query sequences and
constitute rival sites not only to secondary structural elements but also to the 3D fold of the protein
of interest retrieved from deposited PDB files (145). The JASSA prediction alignments revealed
that since SUMO1α shows a complete deficit of the second exon that translates to a lack of the
highly conserved Lysine7, important for SUMO1/2/3 conjugation, as well as 5 other lysine
residues within the second exon with an amino acid difference of 25 residues and 75.2% sequence
similarity. The JASSA predictions further show that SUMO2 and SUMO2α’s difference in exon
2 indicates a 24 amino acid difference with a 74.7% sequence similarity, however, there are no
missing lysine residues. Lastly, SUMO3 and SUMO3α differ from each other by 33 amino acid
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differences with the lowest sequence similarity of 73%, the lowest of the respective SUMO
isoforms. However, these differences are not predicted to translate to any missing or extra lysine
residues thus raising the question of whether both SUMO2α and SUMO3α are capable of not only
conjugating but forming chains.
Although evidence of the existing SUMO1/2/3 variants is strongly supported on the NCBI
database, according to the literature there have been no reports describing the existence of these
variants. Given how common alternative splicing produces isoforms and the RNA-seq data
available, it is a logical summation that alternative splicing may be a potential candidate for the
regulation of the SUMO1/2/3 genes, ultimately regulating itself through a negative feedback
mechanism (based on the existence of different SUMO1/2/3 variants) resulting in de novo
synthesis of multiple proteins being coded from the same gene. While the speed of the changes
observed in our lab’s previous studies of global SUMOylation levels suggests post-transcriptional
regulatory mechanisms at play, it is, therefore, crucial to measure the abundance of SUMO1/2/3
transcripts during infection and other stress conditions to determine whether the changes in global
SUMOylation observed entail changes at the mRNA level as well. In these studies, we have
characterized the alternative splicing of the three SUMO paralogs and determined their functional
properties.
To facilitate our study of the SUMO system at the transcript level, a primer design approach
was created to make use of the differences in the SUMO1/2/3 transcripts by inserting the primers
at the exon/exon junctions to ensure strict amplification of the SUMO1/2/3 messenger RNA
transcripts (Fig. 7). To distinguish SUMO1var1 (345 bp) and SUMO1var2, we designed a primer
to target the area of the 5’ UTR that is spliced out in SUMO1var2 (258 bp). SUMO1var3 (198 bp)
is distinguished by targeting the exon junction formed by the splicing of exon2 out.

42

SUMO2var1(242 bp) and SUMO2var2 (157 bp) are distinguished from each other using this
approach by targeting the exon junction formed through the skipping of exon 3 in SUMO2var2.

Figure 7- Strategy for Independent Targeting of the SUMO1/2/3 Variants
A) Primers were designed to target exon/exon junctions to ensure proper amplification of mRNA
transcripts only. B) Primer design validation through PCR using RNA extracted from Hek293A
cells and confirmed via agarose gel electrophoresis. C) Final confirmation of primer design via
sequencing.

Due to the intronic inclusion generated in SUMO3var2 (239 bp), our primer design approach
targets this area while the primer designed for SUMO3var1 (179 bp) targets the exon junction
formed by exon2 and exon3. These data confirm not only does the cell produce each of the
SUMO1/2/3 variant transcripts, but our method for amplifying each variant independently in a
single qRT-PCR reaction using precisely 100ng of purified RNA is successful (Fig. 7). This
methodology serves as the basis for the further characterization of the SUMO1/2/3 prototype and
alternatively spliced mRNA transcripts for further downstream applications.
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However, to have a true understanding of the precise levels of each transcript within the cell,
it was necessary to then develop a true means of quantification. Calibration curves are an essential
tool for providing these copy number estimates, here denoted, CNest, for each SUMO1/2/3 variant
transcript to establish true overall SUMO1/2/3 combined copy numbers as well as the respective
proportions between each of the paralogs. As outlined in Methods and Materials, beginning with
calculating the predicted weights for each variant, dilutions were carried out through the
quantification of T7 transcribed RNA that indicated the amount of each dilution required for
subsequent qRT-PCR reactions run in triplicates. The quantification of the SUMO1/2/3 variants
reveals an R-value close to 1, giving a consistently greater range of change within the orders of
magnitude present within the serial dilutions. Gel electrophoresis was performed as a last step
quality check (data not shown). The generated calibration curves then made it feasible to detect
the exact copy number of each variant found within A549, HEK293, and Calu-3 cells, all of which
are immortalized cell lines. However, to avoid the detection being based on this characteristic
alone, total RNA was purified from PBM cell lines (Fig. 8).
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Figure 8- SUMO1/2/3 mRNA Normalcy Levels Across Four Mammalian Cell Lines
Cloning of the SUMO1/2/3 variants to establish calibration curves reveal the alternatively spliced SUMO1/2/3
variants are all produced within the eukaryotic cell in different amounts compared to their respective prototypes.
Quantification of all SUMO1/2/3 standard levels in four cell lines using triplicate purifications was obtained
from A549, HEK293A, Calu-3 and PBMC cell lines using three separate RNA purifications all ran in triplicate
qRT-PCR reactions using MyGo machinery. A549 cell SUMO1/2/3 variant levels indicate this cell line with the
highest presence of SUMO1var2 as well as SUMO2var2. Calu-3 SUMO1/2/3 levels exhibit the highest presence
of SUMO3var2. To avoid transcript readouts being based solely in immortalized cells, Peripheral Blood
Mononucleated Cells obtained from three separate live donors reveal the least amount of SUMO3var2 but the
highest levels of SUMO1var3.

The purified RNA from the four mammalian cell lines was used to carry out final one-step qRTPCR reactions ran on MyGo machinery in triplicates using precisely 100ng of mRNA per reaction.
The calibration curve readouts indicate the Hek293A cell contains 19x10" total SUMO transcripts,
the highest amount amongst the compared cell lines. The A549 cell line readouts indicate 11x10"
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total SUMO transcripts, followed by Calu-3 with 9x10" total SUMO transcripts. Lastly, the PBM
cell, the only model derived from live donors exhibits the lowest of total SUMO transcripts with
2x10" CNest (copy number estimates). Across all four cell lines, SUMO2 represents the most
SUMO paralog transcripts, with the HEK293A cell line exhibiting the highest SUMO2 levels
constituting 90% of SUMO transcripts. Of the alternatively spliced transcripts encoding the
SUMO1/2/3 protein isoforms, SUMO1var3 levels, the transcript coding for the isoform,
SUMO1α, is present at almost a 10-fold lower than that of SUMO1var1 and SUMO1var2. While
SUMO2var1 and SUMO2var2 follow a similar trend, the same is not true for SUMO3α’s transcript
which represents 15-38% of total SUMO3 in the cell, the only alternatively spliced variant
predicted to be conjugatable. It is also noteworthy that SUMO2/3 variants levels in PBM cells are
present in the lowest amounts except for SUMO1var3, the only cell line that isn’t exclusively
immortalized. Another observation is regardless of cell sample origin is the transcripts encoding
for each of the alternative isoforms represent the lowest levels. Therefore, by looking at the total
pool of SUMO transcripts as well as the respective ratios of each SUMO1/2/3 paralog gives a
sense of total SUMO contribution as a system and by individual paralog giving further proof that
these alternatively spliced variants found on the NCBI database could contribute differential
functional effects to not only cellular responses but towards the regulation of the SUMO system
itself. It is on this basis that further characterization was needed on the behavior of these
SUMO1/2/3 transcripts.
The cloning of the SUMO1/2/3 variants to establish calibration curves most importantly
revealed the alternatively spliced SUMO1/2/3 variants are all produced within the eukaryotic cell
in different amounts compared to their respective prototypes. In pursuit of the characterization of
the alternatively spliced transcripts in accordance with previous studies, our validated quantitative
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approach for detecting levels of all SUMO1/2/3 variants was then used for testing the response to
stressors all known to trigger global increases in SUMOylation to assess any differences in stress
response amongst the alternatively spliced transcripts (Fig. 9). We hypothesize to mitigate cellular
stress, that SUMO gene expression profiles are altered. More specifically, the transcripts coding
for the prototypical SUMO1/2/3 proteins would be upregulated, while the transcripts encoding for
the SUMOα isoforms would be downregulated in response to the various stressors. Three separate
stress treatments: heat shock at 43C for 1-hour, cold shock at 27C for 24 hours, and H1N1
infections for 12 hours were repeated three times to obtain purified RNA used in triplicate qRTPCR reactions using 100ng of purified mRNA. It is important to note that all purified RNA species
were verified by gel electrophoresis to ensure the quality of purification. Control transcripts were
chosen based on their known documented responses to each respective treatment. The influenza
Matrix gene was chosen due to late expression upon infection demonstrating an average of 256fold increase indicative of successful uptake and production of viral particles in both A549 and
HEK293A cells (Fig.9A/B). RBM3 was the gene used to ensure the cold shock stimulated the
appropriate cellular response at 27°C for 24 hours which showed a 4-fold upregulation compared
to the control treatment (Fig.9A/B). Lastly, the HSP70 transcript was used for heat shock which
showed an average 7-fold increase upon treatment in both A549 and Hek293A cell lines
(Fig.9A/B).
Changes in the relative abundance of the SUMO variants were triggered by the three
aforementioned types of stress. Total RNA was purified and probed for the CNest of each variant.
Untreated cell cultures were plated at equal cell densities and maintained for equal time frames as
forms of controls. Changes in the relative abundance of each SUMO variant were calculated by
subtracting the control from the stressed CNest. All data are shown on the log2 scale which
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represents the average values obtained from the triplicate measurements in three independent
experiments.
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Figure 9- SUMO1/2/3 Variants Transcriptomic Profile Upon Cellular Stress
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Transcripts coding for alternative SUMO1/2/3 isoforms upon exposure to various stressors using triplicate
purifications obtained from A-C: Control Transcripts known to be upregulated for each treatment show each
treatment did induce the correct cellular response. D: A549 and E: HEK293A cell lines were stressed using
three separate RNA purifications all ran in triplicate qRT-PCR reactions using MyGo machinery. F: SUMO1/2/3
transcript responses to SARS-CoV-2 infection in Calu-3 cells. Y-axes indicate the log2 fold change of each
SUMO1/2/3 transcript using generated calibration curves. X-axes are indicative of each stress treatment. G-I:
Heat maps illustrating the extent of differential SUMO1/2/3 gene expression in response to stress. Representation
of averaged control and stress conditions to illustrate the SUMO1/2/3 proportions in a cell. SUMO3var2
represents the transcript with the least abundance, however, this transcript experiences the most variation upon
each stress treatment. Analyses were done based on 100ng of RNA.

Upon 12-hour Influenza A viral infection, SUMO1var1 exhibited a 2-fold upregulation in
A549 cells (Fig. 9C) and a significant 3.5-fold upregulation in the Hek293A cell lines (Fig. 9D).
Upon cold shock, the A549 cell line showed a 2-fold significant upregulation and a 3-fold
upregulation in HEK293A cells. Heat shock induced a 1.2-fold downregulation in both cell lines.
SUMO1var2 showed 1.5 downregulation upon viral infection in both cell lines, while cold shock
induced an average of 2.1 upregulation. Heat shock, however, induced a 1.2-fold downregulation
of the SUMO1var2 transcripts. SUMO1var3 showed a significant 2.7-fold decrease upon viral
infection in A549 cells and a 1.8-fold decrease in the HEK293A cell line. Cold shock induced a
2.1-fold upregulation in A549 cells and a significant 3.4-fold upregulation in the HEK293A cell
line. Lastly, heat shock treatments showed a 1-fold upregulation in both cell lines. SUMO2 is the
first SUMO gene whose two variants show different profiles in the two cell lines. SUMO2var1
showed a significant 2.4-fold upregulation upon H1N1 infection in A549 cells and a 1.3-fold
downregulation in the HEK293A cell lines. Cold shock induced a 1-fold upregulation in A549 and
a 1-fold downregulation in HEK292A cells. However, heat shock treatments caused a 1-fold
downregulation in both cell lines. SUMO2var2 was upregulated 1.3-fold upon infection in A549
cells but caused a 1-fold decrease in HEK293A cell lines. Cold shock again caused the opposite
regulation effects in each cell line; A549 cells experienced a 1.1-fold downregulation whereas
HEK293A cells showed a 1.1-fold upregulation. Heat-shock treatments were the only ones that
caused a similar trend in both cell lines exhibiting a 1.2 upregulation in SUMO2var2 transcripts.
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SUMO3var1 transcripts were upregulated 1.8-fold upon H1N1 infection in A549 cells but
exhibited a 1.2-fold decrease in the HEK293A cell line. Cold shock induced the opposite 1.4-fold
effect in each cell line, A549 cells showed upregulation and HEK293A showed a downregulation.
Heat shock showed a 1-fold upregulation in A549 cells and a 1-fold downregulation in HEK293A
cells. SUMO3var2 transcripts exhibited a 2-fold increase upon viral infection in A549 cells and a
2-fold decrease in HEK293A cells. Cold Shock induced a 1-fold decrease in A549 cells and a 3fold decrease in the HEK293a cell line. Lastly, heat shock-induced the same 1-fold downregulation
in both cell lines.
Although the SUMO1 transcripts appear to have similar responses to the respective treatments
across both cell lines, the same does not hold true for the SUMO2 and SUMO3 transcripts who in
fact exhibit opposite profiles in response to the stressors. Therefore, these trends show differences
in SUMO gene expression profiles in cell lines with different identities. The previous data indicates
the individual transcripts’ response to different stressors, further data analyses were carried out by
considering the overall SUMO1/2/3 system response to the respective stress treatments. An
important first observation is the total pool of SUMO transcripts in each cell goes from 1.5x10"
to 1x10" copy number estimates upon Influenza A infection. However, the SUMO system
increases at the transcript level by 5 million copies upon a 24 cold shock treatment, and an average
increase of 1 million copies upon a 1-hour heat shock treatment (Fig (E/F). Upon heat shock, there
appear to be no significant changes within the SUMO1/2/3 groups further adding to our postulation
of SUMO acting as a transcriptional modifier as opposed to at the protein level in response to
cellular insults given the respective pathways mechanisms. In conclusion, these data are not
consistent with our initial hypothesis as the stresses tested didn’t appear to consistently upregulate
the transcripts encoding for the prototypical proteins nor downregulate the transcripts encoding for
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the SUMOα isoforms. Instead, the SUMO gene expression profiles are altered in a stressdependent and cell-specific manner. Therefore, the various SUMOα isoforms might exist at very
different concentrations in the cell, and alternative splicing might contribute differently toward
regulating the cellular levels of each SUMO protein perhaps with different proteins and isoforms
communicating through crosstalk for recognition and management of specific cellular insults.
Given the impact of the current pandemic, it was important to characterize the SUMO1/2/3
stress responses upon two distinct viral infections to observe is the stress responses upon Influenza
A infection are conserved. The literature now shows SARS-CoV-2 has been reported to block
certain aspects of the cellular SUMOylation response such as the activating enzyme, SAE1, as
well as a “dysregulation” of other genes connected to the SUMOylation pathway (146). The
SUMOylation system was also implicated in aiding the formation of viral ribonucleoprotein
complexes and nucleocapsids (147). Furthermore, it is now proven that SARS-CoV-2 impairs
host protein expression to suppress interferon response (148). The interferon gene was used as a
control transcript upon SARS-CoV-2 infection based on immune response levels showing a 45fold change compared to the control transcript (Fig. 10A).
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Figure 10- SUMO1/2/3 Variants Transcriptomic Profile Upon SARS-CoV-2 Infection
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Transcripts coding for alternative SUMO1/2/3 isoforms upon exposure to SARS-CoV-2 infection using triplicate
purifications ran in triplicate qRT-PCR reactions using precisely 100ng total RNA in both infected and noninfected. A: Control Transcript known to be upregulated upon viral infection indicates a proper cellular response.
B: SUMO1/2/3 transcript responses to SARS-CoV-2 infection in Calu-3 cells. Y-axes indicate the log2 fold
change of each SUMO1/2/3 transcript using generated calibration curves. X-axes are indicative of each
alternatively spliced SUMO1/2/3 transcript response. C: Heat map illustrating the extent of the differential
SUMO1/2/3 transcripts response to SARS-CoV-2 infection in comparison to D: Heat maps illustrating the extent
of differential SUMO1/2/3 gene expression in response to stressors known to induce global levels of cellular
SUMOylation.

Upon 12-hour Influenza A viral infection, SUMO1var1 exhibited an average of 2.3-fold
upregulation in A549 cells and Hek293A cell lines, however, upon SARS-CoV-2 infection in
Calu-3 cells this transcript was downregulated 1.4-fold. SUMO1var2 showed a 1.5-fold
downregulation upon H1N1 infection however this downregulation was less upon SARS-CoV-2
with a 1-fold change (Fig. 10B). SUMO1var3 showed on average a 2.2-fold downregulation upon
H1N1 infection, however, upon SARS-CoV-2 infection, this changed to a 1.1-fold upregulation in
Calu-3 cells. SUMO2var1 transcripts showed an upregulation upon H1N1 in A549 and
downregulation in HEK293A cells, however, upon SARS infection in Calu-3 cells, there was a
1.2-fold downregulation, like that of the HEK293A infection profile. SUMO2var2 was
upregulated in A549 but downregulated in HEKs which was the same profile observed upon
SARS-CoV-2 infection. SUMO3var1 had a strong upregulation in A549 and a slight
downregulation in HEK293A, this downregulation was further upon SARS-CoV-2 in Calu3 cells.
Lastly, while A549 exhibited a 2-fold upregulation upon H1N1 infection, there was a 2-fold
downregulation in HEK293A. This response was not conserved upon SARS-CoV-2 which exhibits
a 1-fold upregulation. Interestingly these data indicate the transcripts encoding for the SUMO1α
and SUMO3α isoforms are the only ones that exhibit some degree of increase, therefore these data
ultimately reveal a type of perturbation in the presence of SARS-CoV-2 in the presence compared
to the normal SUMO1/2/3 cellular stress response corroborating with the current studies of this
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virus’ ability to directly engage host RNAs to dysregulate essential steps including splicing and
dysregulate a highly conserved cellular stress response (148).
Given the nuances observed in the changes in transcript levels in response to stress, it was
necessary to observe nuclear retention to further characterize the relevance of the SUMO1/2/3
variants. The translocation of proteins in and out of the nucleus induces abundant biochemical
changes such as the entry of nuclear proteins for transcription induction, while their export to the
cytoplasm quells the transcription of target genes (149). Hence, these procedures endure as
fundamental methods to assist in the analysis of explicit intracellular occurrences and portrayal of
protein tasks (150). Therefore, subcellular fractionation was performed to determine whether the
variants are potentially translated in both A549 and HEK293A cell lines using Norgen Biotek’s
Cytoplasmic and Nuclear Fractionation Kit as outlined in Methods in Materials (Fig. 11). qRTPCR analyses using strictly 100ng of purified RNA confirmed the existence of all the variants in
both isolated nuclear and cytoplasmic extracts in both cell lines (Fig. 11). The control transcripts
used in these studies show a significant inverse relationship characteristic of transcripts known to
be abundantly expressed in each respective fraction indicative of successful fractionation
procedures (Fig. 11A/B). The U2 gene was chosen as the nuclear transcript control due to its
transcriptomic role in the U2 component of the spliceosome machinery indicating an 80% nuclear
presence in both A549 and HEK293A cell lines (Fig. 11A/B). As a cytoplasmic control, the S14
gene was selected due to comprising the transcriptomic portion of the 40S ribosomal protein
known to be abundantly expressed in the cytosol which exhibits a 90% cytosolic presence using
our fractionation technique. As a last measure control to verify sufficient fractionation, samples
were lysed for western blot and probed for GAPDH which shows a strong profile only within the
cytosol and not the nuclear fraction (Fig. 11C).
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Figure 11- Detection of SUMO1/2/3 Variants in Cytoplasmic Fractions Provides Hints of
Translational Roles
A/B: Fractionated RNA from three respective purifications of A549 and Hek293A cells show all SUMO1/2/3
variants are exported out of the nucleus in different amounts. The alternatively spliced SUMO1/2/3transcripts
that encode SUMO1/2/3 isoform proteins are underlined in red. Statistics were performed using a Two-Way
Anova with p-values = .05 and above being considered significant and graphed.
C: Table summarizing percentages of each SUMO1/2/3 variant present in respective nuclear/cytosolic fraction.
D/E: Control Transcripts for genes known to have a strong presence in respective nuclear/cytosolic fractions in
both A549 and Hek293A cell lines.
F: Agarose gel electrophoresis confirmation of RNA from three respective purifications of A549 and Hek293A
cells are sufficiently fractionated.

While SUMO1var1 and SUMO1var2 code for the same protein, their nuclear/cytosolic RNA level
profiles are contrasting displaying significant disparities in each fraction. This is a peculiar
observation given that at the transcript level their only differences are in the 5’ UTR in which the
fifth exon is spliced into two for SUMO1var2. However, SUMO1var the transcript encoding for
the SUMO1α isoform is present in relatively equal amounts in the respective fractions. When
comparing SUMO2 and SUMO3 fractionated RNA levels, their profiles are also contrasted,
however, SUMO2var2 is the transcript that is present within all four cell lines at the lowest levels
ironically is the transcript with the highest cytoplasmic levels which could be indicative of a
potential strong amplificatory reach. SUMO3 on the other hand has a strong nuclear presence, the
highest of all transcripts in Hek293A cells.
Given the clear distinctions of the alternative SUMO isoforms at both the transcription
level in response to various stressors, a final subcellular fractionation was used to assess whether
the SUMO1/2/3 transcripts nuclear export profiles shift upon 24-hour cold shock in A549 and
HEK293A cell lines, the stress treatment that caused the most significant change (Fig. 12).
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Figure 12- The SUMO1/2/3 alternative transcripts nucleo-cytosolic profiles shift at 27°C
Sub-cellular fractionation was carried out at 27°C and 37°C as a control. U2, S14, and RBM3 gene transcripts
were also used as additional controls. Red circles are indicative of nuclear fractions, green circles are indicative
of cytosolic transcripts. Larger areas indicate an upregulation upon cold shock incubation at 27°C. Overall
SUMO transcripts increase by two million upon cold shock in both A549 and HEK293A cell lines.
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SUMO1var1 which under standard conditions is 68% nuclear and 32% cytosolic, however,
upon cold shock, an extra 14% of total SUMO1var1 transcripts were exported in HEK293A cells
(Fig. 12A). SUMO1var2 transcript experienced an increased export of 7% in A549 cells, however,
SUMO1var3, the transcript encoding for the SUMO1α protein isoform, experienced no nuclear
export fluctuations upon cold shock treatment (Fig. 12A). SUMO2var1 exhibited a 7% increase in
export in the HEK293A cell line, while SUMO2var2 showed a 9% upregulation in nuclear export
(Fig. 12A). SUMO1var1 exhibits a 5% increase in export upon cold shock in the A549 cell line
while SUMO3var2 showed the most significant 20% increase in export in both cell lines. While
these results examine how the individual SUMO1/2/3 transcripts respond to cold shock treatment,
it is important to note how the SUMO system reacts as a whole (Fig. 12B). The reddish hues
represent the nuclear portion, and the greenish hues are all cytosolic transcripts with the legends
indicative of which transcript contributes the most. When comparing the 37°C and 27°C
treatments, there are significant changes. As the areas increase in both cases, the total number of
transcripts is increased upon cold shock, indicating that there is some degree of regulation at the
transcriptional level. While this upregulation in transcripts is not significant, it does provide a basis
for the total SUMO1/2/3 contribution to the overall increases observed. It also makes the point of
increased cytosolic pools and decreased nuclear pools overall, which is an additional contributor
to the increase in global cellular SUMOylation observed. These data ultimately reveal the control
mechanisms: 1) changes in the nucleocytoplasmic distribution of transcripts, 2) changes in total
transcript numbers, and 3) changes at the level of specific SUMO transcript variants.
The establishing of alternatively spliced SUMO1/2/3 cytoplasmic transcripts and these
indications that those pools appear to be under some level of control indicate they may be playing
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a regulatory role, as well as potential other roles at the level of translation potentially co-existing
with the prototypical SUMO1/2/3 proteins.

Figure 13- Ribosome-Sequencing Confirmation of SUMO1/2/3α’s Translation
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The SUMOα-specific sequences were used to search publicly available Ribo-seq datasets. Sequences underlined
are present in the downstream exon, whereas the sequences not underlined are in the upstream exons.

Ribosome profiling is now considered a powerful tool for the global monitoring of in vivo
translation through deep sequencing of ribosome protected mRNA fragments (151). This
methodology is a proven technique in the sense given ribosome associated RNAs are cross-linked
with the ribosomes and fractionated away from free mRNA. The sample is treated with RNase to
chew away all mRNA not directly protected by a ribosome. Once the RNase is inactivated, the
cross-links are broken, the RNA leftover is purified away from the ribosomes, and the mRNA
sequences left are corresponding to ribosome-protected sequences. The SUMO⍺-specific
sequences were used to search publicly available Ribo-seq datasets (Fig. 13). Sequences
underlined are present in the downstream exon, whereas the sequence not underlined is in the
upstream exon. Provides evidence that sequence-specific mRNAs coding for the SUMO⍺’s was
protected by a ribosome hence it was being translated and therefore produced in the cell.
Given the above confirmation of the in vivo translation of the SUMO1/2/3α isoforms,
investigations of the SUMO1/2/3α isoforms then began at the informatic level to assess differences
in tertiary structures that are essential for SUMO conjugation (Fig. 14). Structurally, because the
second exon of SUMO1var3 is spliced out, the mature mRNA is predicted to code for a shorter
version of the protein missing a substantial segment of the n-terminal region, spanning the first
beta-strand and part of the second beta-strand. Therefore, this novel SUMO1 isoform could
translate into a distorted protein that is lacking a major conjugation site, thus altering its function.
Alpha-fold predicts the very heart of the SUMO2α core is severely disrupted in one of the alphahelical structures of the beta-strands are completely gone while the second is partially gone due to
the splicing out of the third exon.
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Artificial intelligence predicts the deletions generated by the alternative splicing of the SUMO1/2α transcripts
to contain disruptions in their respective tertiary structures affecting the central globular structure and therefore
their functionality. While the intronic inclusion that occurs in the SUMO3α transcript is predicted to not affect
the structure, therefore, predicted to be conjugatable.

Lastly, the server predicted SUMO3α to be the only one that is conjugatable given it is the only
SUMO gene whose alternatively spliced variant involves one intronic inclusion. It is important to
note that while the alternative isoforms still contain the alpha helix, the changes in beta strands do
affect the central globular structure and in theory, functionality.
Given the Alpha-fold functionality predictions in conjunction with SUMO1/2/3 detection
within the cytoplasm, functional characteristics were then investigated via the cloning of all
SUMO1/2/3 protein isoforms into a His-Tagged as well as a YFP-Tagged vector. The clones were
then overexpressed in their mature form (diglycine motif at C-end) by transfection in a mammalian
cell line to determine if conjugation to endogenous SUMO targets by immunoblot analyses as
outlined in Methods and Materials occurs (Fig. 15). These data confirmed the prediction of
SUMO3α being the only alternatively spliced SUMO1/2/3 isoform that is capable of conjugating
to cellular substrates (Fig. 15D Lane 7). SUMO1/2α are detected in free form but in low amounts
indicative of instability with potential regulatory roles at the proteasomal degradation level. This
postulation is further confirmed in Panel E Lanes 3 and 5 by YFP-Transfection resulting in a
significantly increased signal that appears to stabilize the alternatively truncated SUMO1/2
proteins. One interesting and peculiar observation to be made is the informatic predictions (Fig.
6B) show the normal prototype SUMO1 vs SUMO1α amino acid sequences are lacking five lysine
residues resulting in a complete lack of conjugation abilities for SUMO1α. However, the same is
not true for SUMO2 and SUMO2α whose amino acid alignments show no missing lysine residues,
yet SUMO2α is un-conjugatable indicative of SUMO2 conjugation occurring through a nonconsensus motif.
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Figure 15- Characterized Functional Properties of the SUMO1/2/3α Isoforms
A: To determine whether the SUMO12/3α can conjugate to cellular substrates, plasmids coding for
SUMO1/2/3His-tags.
B: SUMO1/2/3 YFP-tags were transiently transfected into Hek293A cells and 48h post-transfection the cells
were collected and SUMOylation assessed by western blot on a 10% SDS-Page Gel using anti-S Tag antibodies
and GAPDH as a control for loading normalization.
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Given the confirmed differences in transcript levels in conjunction with their export out of
the nucleus, it was then necessary to investigate another major facet of the SUMOylation system,
localization. We hypothesized that given the SUMO3α-isoform exerts similar functional effects
to that of the SUMO3 prototype, then the SUMO3⍺-isoform should exhibit the same cellular
localization. We began by transiently transfecting Hek293A cells expressing SUMO1/2/3 and
SUMO1/2/3α respectively and then subjected to fluorescence confocal microscopy to detect YFPfusions of SUMO (green channel) and Phalloidin (actin filaments red channel), and DAPI (DNA)
staining from three representative fields of cells post resulted in SUMO1/2/3α localization levels
appearing to be significantly altered in contrast to their respective prototypes (Fig. 16). The profile
for SUMO1 indicates typical localization to the nuclear membrane as corroborated by Su et.al
2002 (63) showing a dotted pattern in the nucleus, however, the signal for SUMO1α exhibits a
more diffused fluorescence in the nucleus as well as cytoplasmic dots (Fig. 16A). The signals for
SUMO2 are also strikingly different, the SUMO2 prototype shows a dotted pattern in the nucleus
while SUMO2α transfected cells exhibit a dominantly diffused nuclear and some diffused
cytosolic signal (Fig. 16C). Lastly, while SUMO3 proteins have been typically documented to
localize to the cytoplasm, in our artificial system, there is a strong dotted and diffused nuclear
signal with no signal in the cytoplasm (Fig. 16E). In contrast to SUMO3α transfected cells exhibit
dotted signal in the nucleus but no diffused fluorescence in the nucleus and show some diffused
fluorescence in the cytoplasm (Fig. 16F). Further co-localization assays will be needed to
determine the precise localization of the SUMO1/2/3 proteins and their respective α-isoforms.

64

Figure 16- SUMO1/2/3a His-Tagged Plasmids Affect SUMO1/2/3 Localization
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Transiently transfected Hek293A cells expressing SUMO1/2/3 and SUMO1/2/3α respectively and then
subjected to fluorescence confocal microscopy to detect the YFP-fusions of SUMO (green channel) and
Phalloidin (actin filaments red channel), and DAPI (DNA) staining from three representative fields of cells. A/B)
SUMO1 and SUMO1α localization levels. C-D) SUMO2 and SUMO2α localization levels. E-F) SUMO3 and
SUMO2α localization levels appear to be strictly nuclear showing nuclear diffusion.

Collectively, the proven viability of the SUMO isoform transcripts, their higher gene
expression upon cold shock, and preferential protein localization within the nuclear compartment
adds to our characterization of these SUMO isoforms as potentially indispensable components for
nuclear machinery.
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5. Conclusions
The differences in transcript proportions in standard and stressed cells, altered levels of
transcripts in the cytoplasm vs nucleus, the changes in functionality effects exhibited by
SUMO3α’s ability to conjugate, and overall differences in localization have not been previously
reported. Our primer design provides the specific targeting of the distinct regions to quantify the
SUMO1/2/3 variants independently indicative of a successfully developed experimental approach.
Moreover, the processing of the SUMO1/2/3 transcripts with 5’ capping and 3’ polyadenylation
of the transcripts to achieve nuclear export implies that the SUMO1/2/3 variant mRNA species are
not merely aberrant products of splicing. We have determined in a given cell, the transcript
encoding for the prototype of each SUMO1/2/3 protein is the transcript with the largest presence.
Amongst the respective SUMO paralog groups, the SUMO2 prototype transcript (SUMO2var1)
represents on average 83% of all SUMO transcripts and 99.4% of all SUMO2 transcripts. The
remaining 0.6% of SUMO2var2 transcripts could explain why Matunis et al. 2021 still observed
substantial SUMO2 levels observed in their knock-out cell lines (152).
Our approach offers a novel examination at SUMO1/2/3 expression levels using copy number
variance estimates indicating these transcripts are extremely sensitive to multiple stressors across
multiple cell lines triggering significant changes. Of the transcripts encoding the alternative protein
isoforms, our data indicates SUMO3var2 behaves more contrarily than SUMO2var2 and
SUMO1var3 in the sense that there are more SUMO3var2 transcripts signifying a larger presence
of the SUMO3 isoform, SUMO3a. However, only SUMO3var2 transcripts undergo significant
changes upon viral infection. Our lab has previously shown SUMOylation regulates the activity of
various Influenza viral proteins by altering the normal proportion of SUMOylated vs. nonSUMOylated viral proteins and is largely upregulated during influenza infections. More
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importantly, large increases in global cellular SUMOylation (~3 fold and higher) have been
proven to block influenza viral replication. Given our data’s overall response to stress, we now
hypothesize the main mechanism regulating the increase in SUMOylation during IAV infection
must be translational or post-translational. Due to these critical roles played by the SUMO1/2/3
proteins in cellular homeostasis and our confirmed differences in localization, it is advantageous
for viral proteins to preferentially become SUMOylated to circumvent proteasomal degradation
compared to being occupied by ubiquitin considering they share consensus sites. In contrast to
heat shock conditions which result in serious misfolding of proteins, therefore upregulating the
SUMO1/2/3 levels at the protein level could then be the band-aid that prevents further degradation
upon stress through the increase of solubility.
According to the literature, the cellular heat and cold shock responses target respectively
different molecular pathways. Cellular cold shock responses typically engage in enhancing
transcription, whereas heat shock cellular responses typically target protein folding. It has been
shown that the SUMO1/2/3 proteins exert a stronger effect on transcriptional machinery by
ensuring a fast and effective assembly of the transcriptional complex. Therefore, a more
pronounced effect in SUMO1/2/3 gene transcription would be evident in the stress response
pathway that focuses on transcript fidelity. Based on our data trends, the increase in fold gene
expression occurs upon cold shock treatment, however, heat shock treatment exhibits a decrease
in SUMO1/2/3 transcription. Despite the stark differences in gene expression, our internal controls
indicate transcription activity in both conditions, thus the transcriptomic profile of each treatment
is specific to the activation or inactivation of genes necessary to mitigate a proper cellar response.
This is indicative of SUMO’s vital role in transcriptional machinery assembly and regulation,
which further corroborates with viral infection where SUMO has been documented to conjugate
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to the RDRPs thus facilitating further viral replication. Although SUMO is considered a posttranslational modifier, perhaps, its role in transcription is more vital to the cell as a modulator as
opposed to the typically thought protein stabilizer.
A more peculiar observation is the nuclear-cytosolic export profile of SUMO1var2 given this
transcript is the only one that doesn’t code for a distinct protein isoform, yet this variant has the
highest nuclear export levels as well as significant responses to each respective treatment in both
cell lines indicating a conserved transcriptomic cellular stress response. Therefore, this production
of this transcript could be to contribute to regulatory functions as shown by the widespread
analyses indicating as many as half of all fluxes in mRNA quantities in response to stress are
caused by fluctuating rates of decay (28). Moreover, microarray experiments have revealed that
40–50% of gene expression fluctuations in response to cellular signals occur at the level of the
mRNA stability (29). Nevertheless, the detection of all SUMO1/2/3 variant transcripts in different
amounts in both the cytoplasmic and nuclear RNA fractions also indicates the SUMO system could
be regulated at more than just the post-transcriptional level as shown by the increase in
SUMO3var2 nuclear export at 27°C. Therefore, export of this transcript as well as the other
isoform transcripts then change according to the needs of the cells to ultimately generate isoform
versions of the respective SUMO1/2/3 proteins. It is proposed here the altered states of
hydrophobicity given the differences in their tertiary structures could be further facilitating the
cellular stress response. Altered functional proteins do occur within nature such as Ubiquitin B, in
which an interpolated frameshift mutation ramifies into a truncated peptide that is lacking the Cterminal glycine (153). The abnormal aggregation of this peptide, known as UBB+1, has further
been linked to Alzheimer's disease (153).
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Until now, tools allowing the distinctions of SUMO2 and SUMO3 both functionally and
biochemically in vivo have been limited due to the high SUMO2/3 sequence conservation (65).
One study found through tryptic digests and MALDI-TOF mass spectrometry analysis of SUMO2
conjugation assays that self-conjugation occurs via Lys11 within a SUMO modification motif and
further mutation of lysine 11 in SUMO2 and SUMO3 blocked the assembly of polymeric chains
(78). These studies state SUMO2 appears to be a better substrate for chain formation than does
SUMO3 indicating the 3-amino acid difference in the N-terminal region appears to be partially
inhibitory to the conjugation of SUMO3. Not only have we shown the differences between
SUMO2 and SUMO3 at the transcript level but also at the protein level given the fact that we have
shown SUMO3a is the only alternatively spliced protein product capable of conjugation which is
peculiar given that the extra amino acids within the intronic inclusion contain no lysine residues
but are completely lacking in both SUMO1 and SUMO2 proteins. Since our data shows the altered
version of SUMO3 proteins are conjugatable, this then raises the question of whether the intronic
inclusion codes for a non-consensus SUMO motif not previously characterized and how this
SUMO3α isoform contributes essential distinct functional roles to the cellular stress response.
These observations also raise the possibility of the α-isoforms forming a competitive substrate
affinity as is the case for other post-translational modifications. A simple direct way to test this
would be to conduct an in vitro binding competition assay using all the components necessary for
SUMO1/2/3 conjugation and test which variant preferably binds to targets.
While the informatic predictions show the normal prototype SUMO1 vs SUMO1α amino acid
sequences are lacking five lysine residues resulting in a complete lack of conjugation abilities for
SUMO1α. However, the same is not true for SUMO2 and SUMO2α whose amino acid alignments
show no missing lysine residues yet SUMO2α is un-conjugatable indicative of SUMO2
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conjugation occurring through a non-consensus motif. Additional regulatory mechanisms can be
ascertained by the differences in conjugation ability as well as the localization which is indicative
of differences in target substrates. The detection of the un-conjugatable SUMO1/2α in free form
in low amounts can be potentially explained by the instability of these translated proteins
contributing regulatory roles at the proteasomal degradation level. This postulation is further
confirmed through the YFP-fusion constructs resulting in a significantly increased signal that
appears to stabilize the alternatively truncated SUMO1/2α proteins. This is a peculiar observation
is that 70-80% of these transcripts encoding for the SUMO1/2α isoforms are exported, the highest
of the seven variants aside from SUMO1var2. However, as stated earlier, given it is considered
more evolutionarily efficient for the cell to dictate mRNA localization because mRNA transcripts
are capable of being translated tens to hundreds of times in response to local stimuli rather than
transporting individual proteins back and forth different cellular compartments (34). These data
apply to this innovative notion branded as the “RNA Signature” hypothesis, in which each mRNA
transcript contains an individualized set of regulatory features that regulate its transport,
localization, and translational control (35).
Considering the cytoprotective effects associated with global increases in cellular
SUMOylation, molecules capable of increasing global cellular SUMOylation could be used to
induce prophylactic and therapeutic broad-spectrum resistance to influenza infection, trigger preadaptive resistance to extreme environmental temperatures, and diminish the tissue damage
triggered by acute ischemic events, including heart attacks, strokes, and perioperative ischemic
events. Our hypothesis of the alternative SUMO1/2/3 isoforms’ functional capabilities may still
play a role in cell survival. These observations point to the mechanism used by alternative
SUMO1/2/3 isoforms to inhibit SUMO conjugation by interacting with these SUMO1/2/3
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consensus sites on the target SUMO substrate and termination of conjugation chains serving as a
dominant-negative inhibitor by establishing competitive reversible interactions with the
SUMO1/2/3 interacting motifs of targeted proteins. Once normal SUMO1/2/3 upregulation has
occurred upon stress, essentially serving as a “break” on the SUMOylation system could be useful
from a therapeutic point of view as well in instances when the SUMOylation system is on overdrive
and can no longer be naturally shut down such is the case of uncontrollable growth (cancer) (5).
Therefore, the ability to manipulate SUMOylation conjugation in conjunction with
chemotherapies might offer a new aspect to cancer treatments as indicated by our SUMO2 data.
We now hypothesize if the SUMO2var1 transcript is expressed 50X times more than SUMO1 and
SUMO3 in a given cell type, then artificially altering the proportion of SUMO2var1 vs
SUMO2var2 in that cell type could inactivate the SUMOylation system for that cell type, while
the effects might be substantially lesser for other cell types. This provides for some degree of
specificity that is ultimately not achievable when using global inhibitors of the SUMOylation
cascade, such as the current Ubc9- or SAE2/1-targeted chemical inhibitors. This is further justified
by Anufrieva et al. 2018 who showed decreased splicing efficiency and global intron retention is
a novel stress response mechanism that may promote the survival of malignant cells following
therapy.
While SUMOylation regulation presently assumes transcript levels for SUMO1/2/3 do not
fluctuate to any significant degree and therefore increases in cellular SUMOylation observed upon
stress are merely products of changes in SUMO conjugation/deconjugation driven by fluctuations
of specific ligases. We now present two changes to this: 1) it does not acknowledge the existence
of alternatively spliced variants for SUMO1/2/3, as this has not been formally reported; and 2)
ignores the substantial increases in global SUMOylation triggered by stress require a concurrent
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increase in the total levels of the SUMO modifiers in the cell. Clearly, alternative splicing,
translational regulation, and feedback from the proteins encoded by the alternatively spliced
transcripts play important regulatory roles in the cellular SUMOylation response. Thus, our
transcriptomic approach challenges the current dogma of how global cellular SUMOylation levels
are regulated, introducing a new theory in which alternative splicing along with the different
protein isoforms produced have key functions in the regulation of the cellular levels and activity
of the SUMO proteins. It is proposed here that small molecules capable of triggering large (>2
fold) global increases in SUMOylation may exert protective effects stimulating potential crosstalk
between the alternative variants and isoforms beginning at the alternative splice level through an
indirect negative feedback mechanism providing further insight to the mechanisms regulating
global SUMOylation levels in the cell.
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6. Limitations of the Study
PBM cells were initially used to simply assess the alternative SUMO variants in a different
cell type to ensure the numbers we were seeing in the Hek293A and A549 cell lines weren’t
exclusive to that of immortalized cell lines alone, because immortalized cell lines have gene
profiles that are not physiologically similar to normal cell lines (74). PBM cell lines are a suitable
option because they are nucleated blood cells and were derived from clinical samples taken from
healthy patients ideally providing a more selective response to the immune system (75). However,
a draw-back to this approach is they are difficult to work with and not sustainable in tissue culture,
thus could no stress conditions on this cell type could be conducted to observe any fluctuations in
the SUMO1/2/3 variants. A pitfall in the cell types that were used to study stress responses,
Hek293A and A549, is they may not be as physiologically relevant due to these cells having
disrupted regulatory and senescence pathways (76), ultimately affecting SUMO expression and
function. An alternative strategy would be to begin experiments in animal models to achieve a
more thorough understanding of our experimental designs. Finally, the collection of samples from
different tissues would provide a more thorough assessment of any tissue-specific effects under
the different stress conditions posited to increase global amounts of SUMOylation within the cell
as seen on the NCBI database.
Based on our Alpha-Fold analyses, we expect SUMO2⍺ to retain its Ubc9- binding ability and
therefore inhibit SUMO2/3 chain formation by a competitive mechanism. Thus, a need to assess
the half-life of SUMO2⍺’s using a pulse-chase approach and perform binding competition assays.
Include a wider set of cellular stress conditions including time courses as well as tissue-specific
samples for both stress treatments and nuclear vs cytosol assay. Further analyses involving the
detection and measurement of endogenous SUMO isoform protein expression would also be
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needed to complement RNA levels through the use of recombinant protein techniques and
generation of antibodies to show the SUMO1/2/3⍺ isoforms are synthesized and analyze stress
responses on the protein level.
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7. Future Directions
During physiological tension such as oxidative stress, SENP1 upregulation has been
documented, consequently decreasing, and disrupting the global SUMO conjugation (154). This
disruption often leads to the subsequent ubiquitination of previously SUMOylated proteins for
proteasomal degradation; a crucial process for protein-turnover rate to assist in the mitigation of
stress (154). Increased expression of these SUMO protease enzymes would thus result in lowered
levels of SUMO1/2/3 conjugation including SUMOylation levels within the nucleus. Because the
SUMOylation system serves as a histone modifier, most often but not always involved in
transcriptional repression (155), SENP1 upregulation during oxidative stress, would therefore also
target these SUMO1/2/3 regulated histone modifications, perhaps increasing SUMO1/2/3
expression. This increase in SUMO expression could lead to the increased half-life of
cytoprotective proteins through the direct interaction of nascent SUMO1/2/3 proteins with the
lysine residues normally found in ambiguous ubiquitin/SUMO consensus sites of substrates, thus
decreasing their protein turnover rate during cellular insult. We hypothesize here, in response to
stress, increased SENP1 expression likely enhances pro-SUMO1/2/3 maturation making more
active SUMO1/2/3 available for conjugation thereby facilitating global SUMOylation and, at the
same time on the background of increased SUMOylation, selectively deconjugates, via SENP1
pathways, SUMO1/2/3 from specific substrates proteins causing an increased presence of
SUMO1/2/3 localized within the nucleus. Transient overexpression of SUMO1/2/3 would
terminate upon the SUMOylation, perhaps at the level of HDACs of histone sites in a stress insultdependent manner. To mitigate the cytoprotective strategy of the SUMOylation system,
SUMO1/2/3 alternative splice variants thus provide the enzymatic diversity from single
transcripts. Ultimately, SUMOylation could result in the remodeling of the spliceosome
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arrangement at multiple steps particularly affecting 5’ donor splice sites which in turn would alter
the splicing of RNA transcripts through ADAR1 editing, providing a SUMO-dependent
enhancement to the output of singular SUMO transcripts. We hypothesize the SUMO system selfregulates the expression of the primary SUMO1/2/3 paralog transcripts through the SUMOylation
of specific components, SRSF1 targets, within the spliceosome complex during the alleviation of
physiological stress, engaging in a negative feedback mechanism that downregulates the
expression of prototypical SUMO1/2/3 paralogs while upregulating the expression of the
alternative SUMO variants and their translated isoforms. The putative molecular mechanism
responsible for the shift of SUMO expression from the prototypical paralogs to SUMO variants
could result from the SUMOylation of spliceosome components in particular the SR proteins who
ensure the coupling of with U1 snRNP by RNA polymerase II at the 5’ splice donor site, resulting
in the alternative splicing of SUMO transcripts. It would also be necessary to investigate the effects
associated with SENP1 transcripts/activity as well as the E3 ligases given their implications in
SUMO’s ability to modify and affect RNA editing. Therefore, transcriptomic studies involving the
analysis of the SUMO conjugating ligases in conjunction with the SUMO proteases are crucial to
assess potential contributing regulation mechanisms at this level.
Evaluations on SUMOα overexpression effects on global cellular SUMOylation triggered by
stress would be needed to assess effects exerted by the SUMOα’s on the global increase in cellular
SUMOylation triggered by stress. Following the same methodology of subjecting the two
mammalian cell lines to different stressors at 8 hours post-transfection to probe for global
SUMOylation levels and cellular stress survival. It is also necessary to further investigate the
translation of SUMO 1/2/3 variants isoforms given translational regulation could be a major
contributor to the regulation of SUMO levels in the cell. A preliminary assessment will involve a
77

standard sucrose gradient approach to fractionate cell extracts derived from cells grown under
normal and stress conditions into monosomal and polysomal (2 or more ribosomes per transcript)
fractions (77). RNA will be purified from each fraction to evaluate the distribution of the variants
by qRT- PCR. Due to the short length of the coding sequence present in the mature SUMO
variants, we expect that there will not be more than 3 ribosomes per transcript at any given point.
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8. Supplementary Data
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Figure S1- Accession Numbers of each SUMO1/2/3 Variant
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Figure S2- Primer Sequences for Amplification of all seven SUMO1/2/3 Variants Independently
Table of primer sequences used for independent detection and amplification of each SUMO1/2/3 variant by
specific targeting of exon/exon distinctions found within each transcript sequence. As well as control transcripts
used in respective stress and fractionation assays.
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Fig. S3 SUMO1/2/3 Stress-Induced Response Levels in the A549 Cell Line
SUMO2 remains the abundant paralog upon all stress treatments ranging from an average of 88.20% transcripts,
experiences a decrease in transcription upon heat shock comprising 83% of SUMO transcripts and a slightly less
decrease upon Influenza A infection (86% of total SUMO transcripts). the largest shift in SUMO proportions
occurs within the SUMO3 transcripts, in which SUMO3var2 which represents on average 25% of the total
SUMO3 mRNA was significantly decreased by 19% of transcripts upon Influenza A viral infection
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Fig. S4 SUMO1/2/3 Stress-Induced Response Levels in the HEK293A Cell Line
SUMO2 remains the abundant paralog upon all stress treatments ranging from an average of 88.20% transcripts,
experiences a decrease in transcription upon heat shock comprising 83% of SUMO transcripts and a slightly less
decrease upon Influenza A infection (86% of total SUMO transcripts). the largest shift in SUMO proportions
occurs within the SUMO3 transcripts, in which SUMO3var2 which represents on average 25% of the total
SUMO3 mRNA was significantly decreased by 19% of transcripts upon Influenza A viral infection
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S5- Graphical Representation of Subcellular Fractionation at 27°C
A) Control Transcripts for each respective fraction and cold shock B) Fractionated Response of
SUMO1/2/3 transcripts in response to cold shock showing standard deviation. C) Table summarizing
the percent of each transcript’s export profile.

83

9. References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.

15.
16.
17.
18.
19.
20.
21.

R. T. Hay, SUMO: a history of modification. Mol Cell 18, 1-12 (2005).
S. Pal, A. Santos, J. M. Rosas, J. Ortiz-Guzman, G. Rosas-Acosta, Influenza A virus interacts
extensively with the cellular SUMOylation system during infection. Virus Res 158, 12-27
(2011).
Y. J. Lee et al., SUMOylation participates in induction of ischemic tolerance. J
Neurochem 109, 257-267 (2009).
Q. J. Quinones, Q. Ma, Z. Zhang, B. M. Barnes, M. V. Podgoreanu, Organ protective
mechanisms common to extremes of physiology: a window through hibernation
biology. Integr Comp Biol 54, 497-515 (2014).
M. Boulanger, R. Paolillo, M. Piechaczyk, G. Bossis, The SUMO Pathway in
Hematomalignancies and Their Response to Therapies. Int J Mol Sci 20, (2019).
J. D. Bernstock et al., SUMOylation in brain ischemia: Patterns, targets, and translational
implications. J Cereb Blood Flow Metab 38, 5-16 (2018).
J. D. WATSON, F. H. CRICK, Molecular structure of nucleic acids; a structure for
deoxyribose nucleic acid. Nature 171, 737-738 (1953).
J. D. WATSON, F. H. CRICK, The structure of DNA. Cold Spring Harb Symp Quant Biol
18, 123-131 (1953).
T. Schneider-Poetsch, M. Yoshida, Along the Central Dogma-Controlling Gene
Expression with Small Molecules. Annu Rev Biochem 87, 391-420 (2018).
F. Hubé, C. Francastel, Mammalian introns: when the junk generates molecular diversity.
Int J Mol Sci 16, 4429-4452 (2015).
B. Heinrich et al., Heterogeneous nuclear ribonucleoprotein G regulates splice site
selection by binding to CC(A/C)-rich regions in pre-mRNA. J Biol Chem 284, 14303-14315
(2009).
S. Yitzhaki, E. Miriami, R. Sperling, J. Sperling, Phosphorylated Ser/Arg-rich proteins:
limiting factors in the assembly of 200S large nuclear ribonucleoprotein particles. Proc
Natl Acad Sci U S A 93, 8830-8835 (1996).
T. R. Mercer et al., Genome-wide discovery of human splicing branchpoints. Genome
Res 25, 290-303 (2015).
S. Saebøe-Larssen, E. Fossberg, G. Gaudernack, Characterization of novel alternative
splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression
and mutual correlation in mRNA isoforms from normal and tumour tissues. BMC Mol
Biol 7, 26 (2006).
M. C. Drummond, K. H. Friderici, A novel actin mRNA splice variant regulates ACTG1
expression. PLoS Genet 9, e1003743 (2013).
D. O. Wise, R. Krahe, B. R. Oakley, The gamma-tubulin gene family in humans. Genomics
67, 164-170 (2000).
E. T. Wang et al., Alternative isoform regulation in human tissue transcriptomes. Nature
456, 470-476 (2008).
J. Parenteau, S. Abou Elela, Introns: Good Day Junk Is Bad Day Treasure. Trends Genet
35, 923-934 (2019).
Y. Shi, Mechanistic insights into precursor messenger RNA splicing by the spliceosome.
Nat Rev Mol Cell Biol 18, 655-670 (2017).
Z. Frankenstein, J. Sperling, R. Sperling, M. Eisenstein, A unique spatial arrangement of
the snRNPs within the native spliceosome emerges from in silico studies. Structure 20,
1097-1106 (2012).
Z. Wang, C. B. Burge, Splicing regulation: from a parts list of regulatory elements to an
integrated splicing code. RNA 14, 802-813 (2008).
84

22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.

M. J. Moore, N. J. Proudfoot, Pre-mRNA processing reaches back to transcription and
ahead to translation. Cell 136, 688-700 (2009).
A. J. Matlin, F. Clark, C. W. Smith, Understanding alternative splicing: towards a cellular
code. Nat Rev Mol Cell Biol 6, 386-398 (2005).
J. Sperling, M. Azubel, R. Sperling, Structure and function of the Pre-mRNA splicing
machine. Structure 16, 1605-1615 (2008).
O. Raitskin, D. S. Cho, J. Sperling, K. Nishikura, R. Sperling, RNA editing activity is
associated with splicing factors in lnRNP particles: The nuclear pre-mRNA processing
machinery. Proc Natl Acad Sci U S A 98, 6571-6576 (2001).
O. Raitskin, M. Angenitzki, J. Sperling, R. Sperling, Large nuclear RNP particles--the
nuclear pre-mRNA processing machine. J Struct Biol 140, 123-130 (2002).
D. R. Schoenberg, L. E. Maquat, Regulation of cytoplasmic mRNA decay. Nat Rev Genet
13, 246-259 (2012).
N. L. Garneau, J. Wilusz, C. J. Wilusz, The highways and byways of mRNA decay. Nat Rev
Mol Cell Biol 8, 113-126 (2007).
C. Cheadle et al., Control of gene expression during T cell activation: alternate
regulation of mRNA transcription and mRNA stability. BMC Genomics 6, 75 (2005).
B. P. Lewis, I. H. Shih, M. W. Jones-Rhoades, D. P. Bartel, C. B. Burge, Prediction of
mammalian microRNA targets. Cell 115, 787-798 (2003).
A. B. Shyu, M. F. Wilkinson, A. van Hoof, Messenger RNA regulation: to translate or to
degrade. EMBO J 27, 471-481 (2008).
R. B. Knowles et al., Translocation of RNA granules in living neurons. J Neurosci 16, 78127820 (1996).
C. Xia, J. Fan, G. Emanuel, J. Hao, X. Zhuang, Spatial transcriptome profiling by MERFISH
reveals subcellular RNA compartmentalization and cell cycle-dependent gene
expression. Proc Natl Acad Sci U S A 116, 19490-19499 (2019).
S. Das, M. Vera, V. Gandin, R. H. Singer, E. Tutucci, Intracellular mRNA transport and
localized translation. Nat Rev Mol Cell Biol 22, 483-504 (2021).
M. Doyle, M. A. Kiebler, Mechanisms of dendritic mRNA transport and its role in
synaptic tagging. EMBO J 30, 3540-3552 (2011).
L. E. Maquat, W. Y. Tarn, O. Isken, The pioneer round of translation: features and
functions. Cell 142, 368-374 (2010).
J. D. Lewis, D. Tollervey, Like attracts like: getting RNA processing together in the
nucleus. Science 288, 1385-1389 (2000).
B. Liu, S. B. Qian, Translational reprogramming in cellular stress response. Wiley
Interdiscip Rev RNA 5, 301-315 (2014).
R. J. Jackson, C. U. Hellen, T. V. Pestova, The mechanism of eukaryotic translation
initiation and principles of its regulation. Nat Rev Mol Cell Biol 11, 113-127 (2010).
N. Sonenberg, A. G. Hinnebusch, Regulation of translation initiation in eukaryotes:
mechanisms and biological targets. Cell 136, 731-745 (2009).
K. Richter, M. Haslbeck, J. Buchner, The heat shock response: life on the verge of death.
Mol Cell 40, 253-266 (2010).
M. Holcik, N. Sonenberg, Translational control in stress and apoptosis. Nat Rev Mol Cell
Biol 6, 318-327 (2005).
L. W. Barrett, S. Fletcher, S. D. Wilton, Regulation of eukaryotic gene expression by the
untranslated gene regions and other non-coding elements. Cell Mol Life Sci 69, 36133634 (2012).
A. V. Zamaraev, G. S. Kopeina, E. A. Prokhorova, B. Zhivotovsky, I. N. Lavrik, Posttranslational Modification of Caspases: The Other Side of Apoptosis Regulation. Trends
Cell Biol 27, 322-339 (2017).
85

45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.

C. T. Walsh, S. Garneau-Tsodikova, G. J. Gatto, Protein posttranslational modifications:
the chemistry of proteome diversifications. Angew Chem Int Ed Engl 44, 7342-7372
(2005).
J. Liu, C. Qian, X. Cao, Post-Translational Modification Control of Innate Immunity.
Immunity 45, 15-30 (2016).
A. S. Venne, L. Kollipara, R. P. Zahedi, The next level of complexity: crosstalk of
posttranslational modifications. Proteomics 14, 513-524 (2014).
M. Buljan et al., Kinase Interaction Network Expands Functional and Disease Roles of
Human Kinases. Mol Cell 79, 504-520.e509 (2020).
L. N. Johnson, The regulation of protein phosphorylation. Biochem Soc Trans 37, 627-641
(2009).
O. Takeuchi, S. Akira, Pattern recognition receptors and inflammation. Cell 140, 805-820
(2010).
A. J. Schile, M. García-Fernández, H. Steller, Regulation of apoptosis by XIAP ubiquitinligase activity. Genes Dev 22, 2256-2266 (2008).
S. Fulda, K. Rajalingam, I. Dikic, Ubiquitylation in immune disorders and cancer: from
molecular mechanisms to therapeutic implications. EMBO Mol Med 4, 545-556 (2012).
P. Hänzelmann, A. Schäfer, D. Völler, H. Schindelin, Structural insights into functional
modes of proteins involved in ubiquitin family pathways. Methods Mol Biol 832, 547-576
(2012).
W. Li, Y. Ye, Polyubiquitin chains: functions, structures, and mechanisms. Cell Mol Life
Sci 65, 2397-2406 (2008).
D. Komander, M. Rape, The ubiquitin code. Annu Rev Biochem 81, 203-229 (2012).
H. M. Chang, E. T. H. Yeh, SUMO: From Bench to Bedside. Physiol Rev 100, 1599-1619 (2020).
A. Galarreta, P. Valledor, O. Fernandez-Capetillo, E. Lecona, Coordinating DNA
Replication and Mitosis through Ubiquitin/SUMO and CDK1. Int J Mol Sci 22, (2021).
R. J. Dohmen, SUMO protein modification. Biochim Biophys Acta 1695, 113-131 (2004).
Y. Laoong-u-thai, B. Zhao, A. Phongdara, H. Ako, J. Yang, Identifications of SUMO-1
cDNA and its expression patterns in Pacific white shrimp Litopeanaeus vannamei. Int J
Biol Sci 5, 205-214 (2009).
J. R. Gareau, C. D. Lima, The SUMO pathway: emerging mechanisms that shape
specificity, conjugation and recognition. Nat Rev Mol Cell Biol 11, 861-871 (2010).
N. Nagaraj et al., Deep proteome and transcriptome mapping of a human cancer cell
line. Mol Syst Biol 7, 548 (2011).
D. Owerbach, L. Piña, K. H. Gabbay, A 212-kb region on chromosome 6q25 containing the
TAB2 gene is associated with susceptibility to type 1 diabetes. Diabetes 53, 1890-1893
(2004).
H. L. Su, S. S. Li, Molecular features of human ubiquitin-like SUMO genes and their
encoded proteins. Gene 296, 65-73 (2002).
A. C. Vertegaal et al., Distinct and overlapping sets of SUMO-1 and SUMO-2 target
proteins revealed by quantitative proteomics. Mol Cell Proteomics 5, 2298-2310 (2006).
M. Boulanger, M. Chakraborty, D. Tempé, M. Piechaczyk, G. Bossis, SUMO and
Transcriptional Regulation: The Lessons of Large-Scale Proteomic, Modifomic and
Genomic Studies. Molecules 26, (2021).
A. Seifert, P. Schofield, G. J. Barton, R. T. Hay, Proteotoxic stress reprograms the
chromatin landscape of SUMO modification. Sci Signal 8, rs7 (2015).
E. T. Yeh, L. Gong, T. Kamitani, Ubiquitin-like proteins: new wines in new bottles. Gene
248, 1-14 (2000).
D. A. Sampson, M. Wang, M. J. Matunis, The small ubiquitin-like modifier-1 (SUMO-1)
consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J
Biol Chem 276, 21664-21669 (2001).
86

69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.

E. Mossessova, C. D. Lima, Ulp1-SUMO crystal structure and genetic analysis reveal
conserved interactions and a regulatory element essential for cell growth in yeast. Mol
Cell 5, 865-876 (2000).
V. Bernier-Villamor, D. A. Sampson, M. J. Matunis, C. D. Lima, Structural basis for E2mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating
enzyme Ubc9 and RanGAP1. Cell 108, 345-356 (2002).
X. J. Yang, S. Grégoire, A recurrent phospho-sumoyl switch in transcriptional repression
and beyond. Mol Cell 23, 779-786 (2006).
S. H. Yang, A. Galanis, J. Witty, A. D. Sharrocks, An extended consensus motif enhances
the specificity of substrate modification by SUMO. EMBO J 25, 5083-5093 (2006).
H. A. Blomster et al., In vivo identification of sumoylation sites by a signature tag and
cysteine-targeted affinity purification. J Biol Chem 285, 19324-19329 (2010).
C. Hoege, B. Pfander, G. L. Moldovan, G. Pyrowolakis, S. Jentsch, RAD6-dependent DNA
repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419, 135-141
(2002).
T. Tammsalu et al., Proteome-wide identification of SUMO2 modification sites. Sci Signal
7, rs2 (2014).
K. Husnjak, J. Keiten-Schmitz, S. Müller, Identification and Characterization of SUMOSIM Interactions. Methods Mol Biol 1475, 79-98 (2016).
A. C. Vertegaal, SUMO chains: polymeric signals. Biochem Soc Trans 38, 46-49 (2010).
M. H. Tatham et al., Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein
substrates by SAE1/SAE2 and Ubc9. J Biol Chem 276, 35368-35374 (2001).
Y. Xu et al., Induction of SENP1 in endothelial cells contributes to hypoxia-driven VEGF
expression and angiogenesis. J Biol Chem 285, 36682-36688 (2010).
T. Bawa-Khalfe, J. Cheng, Z. Wang, E. T. Yeh, Induction of the SUMO-specific protease 1
transcription by the androgen receptor in prostate cancer cells. J Biol Chem 282, 3734137349 (2007).
D. Bailey, P. O'Hare, Characterization of the localization and proteolytic activity of the
SUMO-specific protease, SENP1. J Biol Chem 279, 692-703 (2004).
H. Dou, C. Huang, M. Singh, P. B. Carpenter, E. T. Yeh, Regulation of DNA repair through
deSUMOylation and SUMOylation of replication protein A complex. Mol Cell 39, 333-345
(2010).
T. Bawa-Khalfe et al., Differential expression of SUMO-specific protease 7 variants
regulates epithelial-mesenchymal transition. Proc Natl Acad Sci U S A 109, 17466-17471
(2012).
I. A. Hendriks, A. C. Vertegaal, A comprehensive compilation of SUMO proteomics. Nat
Rev Mol Cell Biol 17, 581-595 (2016).
I. A. Hendriks et al., Site-specific mapping of the human SUMO proteome reveals comodification with phosphorylation. Nat Struct Mol Biol 24, 325-336 (2017).
K. Nacerddine et al., The SUMO pathway is essential for nuclear integrity and
chromosome segregation in mice. Dev Cell 9, 769-779 (2005).
I. Psakhye, S. Jentsch, Protein group modification and synergy in the SUMO pathway as
exemplified in DNA repair. Cell 151, 807-820 (2012).
N. Raman, A. Nayak, S. Muller, The SUMO system: a master organizer of nuclear protein
assemblies. Chromosoma 122, 475-485 (2013).
E. Rosonina, A. Akhter, Y. Dou, J. Babu, V. S. Sri Theivakadadcham, Regulation of
transcription factors by sumoylation. Transcription 8, 220-231 (2017).
P. Chymkowitch, A. Nguéa P, J. M. Enserink, SUMO-regulated transcription: challenging
the dogma. Bioessays 37, 1095-1105 (2015).
T. Phillips. (Nature Education, 2008), vol. 1( 1 ) :199.
87

92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.

G. Gill, Something about SUMO inhibits transcription. Curr Opin Genet Dev 15, 536-541
(2005).
S. H. Yang, E. Jaffray, R. T. Hay, A. D. Sharrocks, Dynamic interplay of the SUMO and
ERK pathways in regulating Elk-1 transcriptional activity. Mol Cell 12, 63-74 (2003).
J. Kim, C. A. Cantwell, P. F. Johnson, C. M. Pfarr, S. C. Williams, Transcriptional activity
of CCAAT/enhancer-binding proteins is controlled by a conserved inhibitory domain
that is a target for sumoylation. J Biol Chem 277, 38037-38044 (2002).
S. Muller et al., c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem
275, 13321-13329 (2000).
G. Rosas-Acosta, W. K. Russell, A. Deyrieux, D. H. Russell, V. G. Wilson, A universal
strategy for proteomic studies of SUMO and other ubiquitin-like modifiers. Mol Cell
Proteomics 4, 56-72 (2005).
K. Struhl, Fundamentally different logic of gene regulation in eukaryotes and
prokaryotes. Cell 98, 1-4 (1999).
D. Sproul, N. Gilbert, W. A. Bickmore, The role of chromatin structure in regulating the
expression of clustered genes. Nat Rev Genet 6, 775-781 (2005).
M. Garcia-Dominguez, J. C. Reyes, SUMO association with repressor complexes,
emerging routes for transcriptional control. Biochim Biophys Acta 1789, 451-459 (2009).
B. Lee, C. Y. Wu, Y. W. Lin, S. W. Park, L. N. Wei, Synergistic activation of Arg1 gene by
retinoic acid and IL-4 involves chromatin remodeling for transcription initiation and
elongation coupling. Nucleic Acids Res 44, 7568-7579 (2016).
S. Clancy, W. Brown. (Nature Education 1( 1 ) :101, 2008).
H. Neyret-Kahn et al., Sumoylation at chromatin governs coordinated repression of a
transcriptional program essential for cell growth and proliferation. Genome Res 23,
1563-1579 (2013).
P. K. Nuro-Gyina, J. D. Parvin, Roles for SUMO in pre-mRNA processing. Wiley
Interdiscip Rev RNA 7, 105-112 (2016).
K. Song et al., Transcriptome Analysis of Flowering Time Genes under Drought Stress
in Maize Leaves. Front Plant Sci 8, 267 (2017).
S. R. Thatcher et al., Genome-Wide Analysis of Alternative Splicing during
Development and Drought Stress in Maize. Plant Physiol 170, 586-599 (2016).
J. A. Pleiss, G. B. Whitworth, M. Bergkessel, C. Guthrie, Rapid, transcript-specific changes
in splicing in response to environmental stress. Mol Cell 27, 928-937 (2007).
M. A. Garcia-Blanco, Messenger RNA reprogramming by spliceosome-mediated RNA
trans-splicing. J Clin Invest 112, 474-480 (2003).
B. Pozzi et al., SUMO conjugation to spliceosomal proteins is required for efficient premRNA splicing. Nucleic Acids Res 45, 6729-6745 (2017).
P. Richard, V. Vethantham, J. L. Manley, Roles of Sumoylation in mRNA Processing and
Metabolism. Adv Exp Med Biol 963, 15-33 (2017).
T. Geuens, D. Bouhy, V. Timmerman, The hnRNP family: insights into their role in
health and disease. Hum Genet 135, 851-867 (2016).
F. Pelisch et al., The serine/arginine-rich protein SF2/ASF regulates protein
sumoylation. Proc Natl Acad Sci U S A 107, 16119-16124 (2010).
R. Das et al., SR proteins function in coupling RNAP II transcription to pre-mRNA
splicing. Mol Cell 26, 867-881 (2007).
J. M. Desterro et al., SUMO-1 modification alters ADAR1 editing activity. Mol Biol Cell 16,
5115-5126 (2005).
T. Sternsdorf, K. Jensen, B. Reich, H. Will, The nuclear dot protein sp100, characterization
of domains necessary for dimerization, subcellular localization, and modification by
small ubiquitin-like modifiers. J Biol Chem 274, 12555-12566 (1999).
88

115.
116.
117.
118.
119.
120.

121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.

T. Bawa-Khalfe, E. T. Yeh, SUMO Losing Balance: SUMO Proteases Disrupt SUMO
Homeostasis to Facilitate Cancer Development and Progression. Genes Cancer 1, 748-752
(2010).
M. H. Tatham et al., RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for
arsenic-induced PML degradation. Nat Cell Biol 10, 538-546 (2008).
Z. Dassouki et al., ATL response to arsenic/interferon therapy is triggered by
SUMO/PML/RNF4-dependent Tax degradation. Blood 125, 474-482 (2015).
V. Lallemand-Breitenbach et al., Arsenic degrades PML or PML-RARalpha through a
SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10, 547-555 (2008).
J. J. Driscoll et al., The sumoylation pathway is dysregulated in multiple myeloma and
is associated with adverse patient outcome. Blood 115, 2827-2834 (2010).
J. Xu et al., SENP1 inhibition induces apoptosis and growth arrest of multiple myeloma
cells through modulation of NF-κB signaling. Biochem Biophys Res Commun 460, 409415 (2015).
H. J. Huang et al., β-catenin SUMOylation is involved in the dysregulated proliferation
of myeloma cells. Am J Cancer Res 5, 309-320 (2015).
J. D. Kessler et al., A SUMOylation-dependent transcriptional subprogram is required
for Myc-driven tumorigenesis. Science 335, 348-353 (2012).
B. Yu et al., Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase
Ubc9. Proc Natl Acad Sci U S A 112, E1724-1733 (2015).
S. W. Kmiecik, K. Drzewicka, F. Melchior, M. P. Mayer, Heat shock transcription factor 1
is SUMOylated in the activated trimeric state. J Biol Chem 296, 100324 (2021).
H. Saitoh, J. Hinchey, Functional heterogeneity of small ubiquitin-related protein
modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 275, 6252-6258 (2000).
E. A. Niskanen, J. J. Palvimo, Chromatin SUMOylation in heat stress: To protect, pause
and organise?: SUMO stress response on chromatin. Bioessays 39, (2017).
F. Liebelt et al., SUMOylation and the HSF1-Regulated Chaperone Network Converge to
Promote Proteostasis in Response to Heat Shock. Cell Rep 26, 236-249.e234 (2019).
F. Golebiowski et al., System-wide changes to SUMO modifications in response to heat
shock. Sci Signal 2, ra24 (2009).
H. Cimarosti et al., Enhanced SUMOylation and SENP-1 protein levels following oxygen
and glucose deprivation in neurones. J Cereb Blood Flow Metab 32, 17-22 (2012).
J. A. Tan et al., Protein inhibitors of activated STAT resemble scaffold attachment
factors and function as interacting nuclear receptor coregulators. J Biol Chem 277, 1699317001 (2002).
Y. J. Lee, Y. Mou, D. Klimanis, J. D. Bernstock, J. M. Hallenbeck, Global SUMOylation is a
molecular mechanism underlying hypothermia-induced ischemic tolerance. Front Cell
Neurosci 8, 416 (2014).
O. Anczuków et al., The splicing factor SRSF1 regulates apoptosis and proliferation to
promote mammary epithelial cell transformation. Nat Struct Mol Biol 19, 220-228 (2012).
Z. Zhang, A. R. Krainer, Involvement of SR proteins in mRNA surveillance. Mol Cell 16,
597-607 (2004).
Y. Huang, R. Gattoni, J. Stévenin, J. A. Steitz, SR splicing factors serve as adapter proteins
for TAP-dependent mRNA export. Mol Cell 11, 837-843 (2003).
S. Sun, Z. Zhang, R. Sinha, R. Karni, A. R. Krainer, SF2/ASF autoregulation involves
multiple layers of post-transcriptional and translational control. Nat Struct Mol Biol 17,
306-312 (2010).
S. Das, A. R. Krainer, Emerging functions of SRSF1, splicing factor and oncoprotein, in
RNA metabolism and cancer. Mol Cancer Res 12, 1195-1204 (2014).
89

137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.

L. Twyffels, C. Gueydan, V. Kruys, Shuttling SR proteins: more than splicing factors.
FEBS J 278, 3246-3255 (2011).
A. I. Lamond, D. L. Spector, Nuclear speckles: a model for nuclear organelles. Nat Rev
Mol Cell Biol 4, 605-612 (2003).
G. Bossis, F. Melchior, SUMO: regulating the regulator. Cell Div 1, 13 (2006).
T. Nishida, H. Tanaka, H. Yasuda, A novel mammalian Smt3-specific isopeptidase 1
(SMT3IP1) localized in the nucleolus at interphase. Eur J Biochem 267, 6423-6427 (2000).
L. Gong, S. Millas, G. G. Maul, E. T. Yeh, Differential regulation of sentrinized proteins
by a novel sentrin-specific protease. J Biol Chem 275, 3355-3359 (2000).
A. Gärtner et al., Acetylation of SUMO2 at lysine 11 favors the formation of non-canonical
SUMO chains. EMBO Rep 19, (2018).
S. Wang, W. Li, S. Liu, J. Xu, RaptorX-Property: a web server for protein structure
property prediction. Nucleic Acids Res 44, W430-435 (2016).
S. M. Mortuza et al., Improving fragment-based ab initio protein structure assembly
using low-accuracy contact-map predictions. Nat Commun 12, 5011 (2021).
G. Beauclair, A. Bridier-Nahmias, J. F. Zagury, A. Saïb, A. Zamborlini, JASSA: a
comprehensive tool for prediction of SUMOylation sites and SIMs. Bioinformatics 31,
3483-3491 (2015).
I. H. Ibrahim, D. E. Ellakwa, SUMO pathway, blood coagulation and oxidative stress in
SARS-CoV-2 infection. Biochem Biophys Rep 26, 100938 (2021).
A. K. Banerjee et al., SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking
to Suppress Host Defenses. Cell 183, 1325-1339.e1321 (2020).
X. Lei et al., Activation and evasion of type I interferon responses by SARS-CoV-2. Nat
Commun 11, 3810 (2020).
R. Hill, B. Cautain, N. de Pedro, W. Link, Targeting nucleocytoplasmic transport in
cancer therapy. Oncotarget 5, 11-28 (2014).
V. V. Senichkin, E. A. Prokhorova, B. Zhivotovsky, G. S. Kopeina, Simple and Efficient
Protocol for Subcellular Fractionation of Normal and Apoptotic Cells. Cells 10, (2021).
G. A. Brar, J. S. Weissman, Ribosome profiling reveals the what, when, where and how of
protein synthesis. Nat Rev Mol Cell Biol 16, 651-664 (2015).
D. Bouchard et al., SUMO paralogue-specific functions revealed through systematic
analysis of human knockout cell lines and gene expression data. Mol Biol Cell 32, 18491866 (2021).
R. J. Gentier, F. W. van Leeuwen, Misframed ubiquitin and impaired protein quality
control: an early event in Alzheimer's disease. Front Mol Neurosci 8, 47 (2015).
R. Ma et al., DUSP6 SUMOylation protects cells from oxidative damage via direct
regulation of Drp1 dephosphorylation. Sci Adv 6, eaaz0361 (2020).
D. Nathan et al., Histone sumoylation is a negative regulator in Saccharomyces
cerevisiae and shows dynamic interplay with positive-acting histone modifications.
Genes Dev 20, 966-976 (2006).

90

10. Vita
Myriah Acuña is a native El Pasoan, who earned her Associate of Science in Chemistry from
El Paso Community College in 2013. She enrolled in the University of Texas at El Paso and
earned her Bachelor of Science in Forensic Biology in 2014. That same year, she entered
graduate school at UTEP in the Master of Biological Science program. Upon the completion
of her M.Sc., Myriah transferred into the UTEP Pathobiology PH. D program under her same
mentor, Dr. German Rosas-Acosta. She proposed her dissertation and entered doctoral
candidacy in Fall 2020 while teaching many courses such as anatomy and physiology, phage
hunters, microbiology, and molecular cell biology.

This dissertation was typed by:
Myriah L. Acuña
Myriahlorraineacuna@gmail.com

91

